Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 424 articles: HTML format

Single Articles

September 2025
1. OKOYE M, Okoi C, Espy N, Mba N, et al
   Leveraging PEPFAR- and Global Fund-Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria.
   J Infect Dis. 2025;232.
   PubMed     Abstract available
   
   
   
2. ALEMNJI G, Sangthong A, Espy N, Bartee M, et al
   PEPFAR Laboratory Implementation Strategy as a Component of PEPFAR's 5-Year Strategy.
   J Infect Dis. 2025;232.
   PubMed     Abstract available
   
   
   
3. LIM SY, Lee J, Kwon JS, Chang E, et al
   Disparate kinetics of viable virus shedding in immunocompromised patients: SARS-CoV-2 versus influenza virus - a prospective real-world cohort study.
   J Infect Dis. 2025 Sep 15:jiaf479. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. WANG C, Yuan HY, Lau EHY, Cowling BJ, et al
   Impact of Population Immunity and Public Health Measures on the Transmission of Omicron Subvariants BA.2 and BA.5 in Hong Kong.
   J Infect Dis. 2025;232:e476-e485.
   PubMed     Abstract available
   
   
   
5. HAMILTON F, Butler-Laporte G, Davey Smith G
   Mendelian Randomization and Infection: Pitfalls and Promises.
   J Infect Dis. 2025;232:525-533.
   PubMed     Abstract available
   
   
   
6. DOSS CR, Osborn MJ, Stark S, Rhein J, et al
   Wastewater Measures of SARS-CoV-2 Accurately Predict Frequency of Symptomatic Infections in the Community.
   J Infect Dis. 2025;232:e459-e465.
   PubMed     Abstract available
   
   
   
7. LI K, Pitzer VE, Weinberger DM
   Exploring RSV Transmission Patterns in Different Age Groups in the United States.
   J Infect Dis. 2025;232:700-708.
   PubMed     Abstract available
   
   
   
8. LI K, Bont LJ, Weinberger DM, Pitzer VE, et al
   Relating In Vivo Respiratory Syncytial Virus Infection Kinetics to Host Infectiousness in Different Age Groups.
   J Infect Dis. 2025;232:691-699.
   PubMed     Abstract available
   
   
   
9. GAILLET A, Layese R, Fourati S, Celante H, et al
   Clinical Phenotypes and Outcomes Associated With Respiratory Syncytial Virus Infection in Critically Ill Patients: A Retrospective Multicenter Cohort Study in Greater Paris Area Hospitals, 2017-2023.
   J Infect Dis. 2025;232:679-690.
   PubMed     Abstract available
   
   
   
10. BERMEJO-JAMBRINA M, Zaderer V, Eder J, Diem G, et al
    The Role of Enoxaparin in Influenza Virus Infections and Its Therapeutic Implications.
    J Infect Dis. 2025 Sep 10:jiaf470. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
11. WESTERHOF I, Sikkema R, Rozhnova G, van Beek J, et al
    The Effect of Preexisting Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Infection Outcomes in Exposed Household Members.
    J Infect Dis. 2025;232:e318-e326.
    PubMed     Abstract available
    
    
    
12. PASANEN A, Karjalainen MK, Korppi M, Hallman M, et al
    Genetic Susceptibility to Acute Viral Bronchiolitis.
    J Infect Dis. 2025;232:e193-e202.
    PubMed     Abstract available
    
    
    
13. ESPERSEN C, Johansen ND, Modin D, Janstrup KH, et al
    Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score: A post-hoc analysis of the DANFLU-1 randomized trial.
    J Infect Dis. 2025 Aug 13:jiaf420. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. WONG JY, Cheung JK, Iuliano AD, Wu P, et al
    Influenza-associated excess mortality associated with influenza B in Hong Kong, 2014-2023.
    J Infect Dis. 2025 Aug 6:jiaf414. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
15. MATEJA A, Chu E, Murray TA, Bramante CT, et al
    The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death.
    J Infect Dis. 2025;232:60-68.
    PubMed     Abstract available
    
    
    
16. FITZPATRICK T, Buchan SA, Mahant S, Fu L, et al
    Pediatric Acute Respiratory Virus Hospitalizations: A Population-Based Cohort Study, 2017-2024.
    J Infect Dis. 2025;232:e137-e149.
    PubMed     Abstract available
    
    
    
17. OBER V, Volk F, Sbierski-Kind J, Gruner E, et al
    Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post-COVID Syndrome.
    J Infect Dis. 2025;232:50-59.
    PubMed     Abstract available
    
    
    
18. BEGIER E, Aliabadi N, Ramirez JA, McGeer A, et al
    Detection by Nasopharyngeal Swabs Alone Underestimates Respiratory Syncytial Virus-Related Hospitalization Incidence in Adults: The Multispecimen Study's Final Analysis.
    J Infect Dis. 2025;232:e126-e136.
    PubMed     Abstract available
    
    
    
19. DE SCHRIJVER S, Vanhulle E, Ingenbleek A, Alexakis L, et al
    Epidemiological and Clinical Insights into Enterovirus Circulation in Europe, 2018-2023: A Multicenter Retrospective Surveillance Study.
    J Infect Dis. 2025;232:e104-e115.
    PubMed     Abstract available
    
    
    
20. CAILLAULT A, Softic L, Bay P, Ly A, et al
    Molecular Characterization of Respiratory Syncytial Virus Infections in Elderly Patients During the 2023-2024 Season in the Era of Nirsevimab Introduction.
    J Infect Dis. 2025;232:199-202.
    PubMed     Abstract available
    
    
    
21. ZHOU JR, Liao Y, Cao LQ, Ma R, et al
    Interleukin 6 Is Significantly Increased in Severe Pneumonia After Allo-Hematopoietic Stem Cell Transplantation and Might Induce Lung Injury via IL-6/sIL-6R/JAK1/STAT3 Pathway.
    J Infect Dis. 2025;232:113-126.
    PubMed     Abstract available
    
    
    
22. EPSI NJ, Chenoweth JG, Blair PW, Lindholm DA, et al
    Precision Symptom Phenotyping Identifies Early Clinical and Proteomic Predictors of Distinct COVID-19 Sequelae.
    J Infect Dis. 2025;232:39-49.
    PubMed     Abstract available
    
    
    
23. SIMOES EAF, Suss RJ, Raje DV
    Human Metapneumovirus, Respiratory Syncytial Virus and Influenza Associated Pneumonia Hospitalizations in Colorado Adults Aged Over 50 Years: 2016-2023.
    J Infect Dis. 2025 Jul 21:jiaf381. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. BILLARD MN, Wildenbeest JG, Kole R, Rodgers-Gray B, et al
    Post-Pandemic Dynamics of the Global Circulation of Human Metapneumovirus and Respiratory Syncytial Virus.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
25. AMINISANI N, Fanslow B, Wood T, Jelley L, et al
    The Burden of HMPV- and Influenza-Associated Hospitalizations in Adults in New Zealand Before and After the COVID-19 Pandemic, 2012-2023.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
26. SAMORISKI C, Chu CY, Falsey AR, Peterson D, et al
    Clinical Features and Gene Expression Patterns in Adults Hospitalized With Respiratory Syncytial Virus and Human Metapneumovirus Infection.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
27. BHASKAR N, Abul Y, DeVone F, McConeghy KW, et al
    Outcomes of Human Metapneumovirus Infections in Nursing Home Residents: A Matched Cohort Analysis.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
28. LOUBET P, Guitton S, Rolland S, Lefrancois LH, et al
    Characteristics of Human Metapneumovirus Infection Compared to Respiratory Syncytial Virus and Influenza Infections in Adults Hospitalized for Influenza-Like Illness in France, 2012-2022.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
29. SIMOES EAF, Suss RJ, Raje D
    Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults >/=50 Years of Age: 2016-2023.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
30. BASSIOUNI SS, Foster-Tucker JE, Callear AP, Godonou ET, et al
    A Comparative Profile of the Burden of Human Metapneumovirus, Respiratory Syncytial Virus, and Influenza in the HIVE Cohort, 2010-2022.
    J Infect Dis. 2025;232.
    PubMed     Abstract available
    
    
    
31. RUMFELT KE, Juntila C, Smith M, Callear A, et al
    Strength and Durability of Respiratory Syncytial Virus Prefusion F Immunoglobulin G Following Infection and Exposure in a Household Cohort, 2014-2022.
    J Infect Dis. 2025;231:e1138-e1145.
    PubMed     Abstract available
    
    
    
32. HEDBERG P, Serwin K, Francesca Greco M, P V Pereira J, et al
    Bacterial and Viral Coinfections in Adult Patients Hospitalized With COVID-19 Throughout the Pandemic: A Multinational Cohort Study in the EuCARE Project.
    J Infect Dis. 2025;231:e1091-e1101.
    PubMed     Abstract available
    
    
    
33. NGUYEN BT, Bertrand J, Agyeman AA, Zhang S, et al
    A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.
    J Infect Dis. 2025;231:e1080-e1090.
    PubMed     Abstract available
    
    
    
34. MANUELPILLAI B, Lopman B, Doran CR, Porter C, et al
    The Impact of Coronavirus Disease 2019 Nonpharmaceutical Interventions on Incidence of Acute Gastroenteritis and Acute Respiratory Infections Among US Military and Dependents.
    J Infect Dis. 2025;231:e1075-e1079.
    PubMed     Abstract available
    
    
    
35. BARTSCH SM, Chin KL, Strych U, John DC, et al
    The Current and Future Burden of Long COVID in the United States.
    J Infect Dis. 2025;231:1581-1590.
    PubMed     Abstract available
    
    
    
36. WHITE CL, Richards KA, Huertas N Jr, Nayak JL, et al
    Human HKU1-Reactive CD4 T Cells Are Enriched for Cytolytic Potential That Persists in Older Adults.
    J Infect Dis. 2025;231:1591-1596.
    PubMed     Abstract available
    
    
    
37. OKABE H, Hashimoto K, Norito S, Asano Y, et al
    Amino Acid Substitutions in the Fusion Protein of Respiratory Syncytial Virus in Fukushima, Japan, During 2008-2023 and Their Effects.
    J Infect Dis. 2025;231:1544-1552.
    PubMed     Abstract available
    
    
    
38. HALL VG, Nguyen THO, Smibert OC, Allen LF, et al
    Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial.
    J Infect Dis. 2025 Jul 2:jiaf297. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
39. GUILFOYLE K, Mirolo M, de Waal L, van Amerongen G, et al
    Highly Pathogenic Avian Influenza Virus A/H5N1 subclade 2.3.4.4 b isolated from a European grey seal (Halichoerus grypus) is highly virulent in ferrets.
    J Infect Dis. 2025 Jun 28:jiaf348. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. LU Y, Allen JD, Ross TM, Cowling B, et al
    Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: a Secondary Analysis of an Animal Challenge Trial.
    J Infect Dis. 2025 Jun 20:jiaf331. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. KING LM, Bruxvoort KJ, Tartof SY, Lewnard JA, et al
    Pediatric antibiotic use associated with respiratory syncytial virus and influenza in the United States, 2008-2018.
    J Infect Dis. 2025 Jun 7:jiaf309. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. NAYAGAM SN, Coote W, Carroll MT, Toh ZQ, et al
    Differentiating SARS-CoV-2 antibody responses between infection and vaccination: challenges for epidemiological research.
    J Infect Dis. 2025 Jun 3:jiaf295. doi: 10.1093.
    PubMed    
    
    
    
43. KNOX JJ, Lee I, Blumberg EA, Rosenfeld AM, et al
    B-Cell Subset Representation Predicts SARS-CoV-2 Vaccine Response in Solid Organ Transplant Recipients.
    J Infect Dis. 2025 Jun 3:jiaf250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. REICHERZ F, Vineta Paramo M, Bone JN, Lavoie A, et al
    Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections.
    J Infect Dis. 2025;231:e840-e845.
    PubMed     Abstract available
    
    
    
45. BAUMGARDT M, Obermayer B, Balazs A, Lowa A, et al
    SARS-CoV-2 Infection of Human Lung Air-Liquid Interface Cultures Reveals Basal Cells as Relevant Targets.
    J Infect Dis. 2025;231:1210-1220.
    PubMed     Abstract available
    
    
    
46. DI GERMANIO C, Marques de Menezes EG, Clevenger R, Rines I, et al
    Viral and Immune Factors Associated With COVID-19 Outcome in the C3PO Trial of Convalescent Plasma.
    J Infect Dis. 2025;231:1198-1209.
    PubMed     Abstract available
    
    
    
47. LENNOL MP, Garcia-Ayllon MS, Aviles-Granados C, Trasciatti C, et al
    Increased Cerebrospinal Fluid Angiotensin-Converting Enzyme 2 Fragments as a Read-Out of Brain Infection in Patients With COVID-19 Encephalopathy.
    J Infect Dis. 2025;231:e929-e940.
    PubMed     Abstract available
    
    
    
48. ZIDAR DA, McComsey GA, Anthony DD, McDaniel J, et al
    Distinct Cytokine Patterns Identify Acute and Convalescent Myocardial Involvement After Coronavirus Disease 2019: A Multicohort Biomarker Study.
    J Infect Dis. 2025;231:e918-e920.
    PubMed     Abstract available
    
    
    
49. RIEDMANN U, Chalupka A, Richter L, Sprenger M, et al
    Estimates of SARS-CoV-2 Infections and Population Immunity After the COVID-19 Pandemic in Austria: Analysis of National Wastewater Data.
    J Infect Dis. 2025;231:e921-e928.
    PubMed     Abstract available
    
    
    
50. URCHUEGUIA-FORNES A, Munoz-Quiles C, Mira-Iglesias A, Lopez-Lacort M, et al
    Ten-Year Surveillance of Respiratory Syncytial Virus Hospitalizations in Adults: Incidence Rates and Case Definition Implications.
    J Infect Dis. 2025;231:e830-e839.
    PubMed     Abstract available
    
    
    
51. HOUDE L, Law AW, Averin A, Weycker D, et al
    Annual Clinical and Economic Burden of Medically Attended Lower Respiratory Tract Illnesses Due to Respiratory Syncytial Virus Among US Infants Aged <12 Months.
    J Infect Dis. 2025;231:1318-1326.
    PubMed     Abstract available
    
    
    
52. OZTURK A, Chan M, Khan JR, Hu N, et al
    Clinical Characteristics and In-hospital Outcomes Associated With Respiratory Syncytial Virus vs Other Viral Acute Lower Respiratory Infections in Hospitalized Children Younger Than 2 Years.
    J Infect Dis. 2025;231:1309-1317.
    PubMed     Abstract available
    
    
    May 2025
53. BAUM HE, Santopaolo M, Francis O, Milodowski EJ, et al
    Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.
    J Infect Dis. 2025 May 20:jiaf246. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. ZHU S, Quint J, Leon T, Sun M, et al
    Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season.
    J Infect Dis. 2025 May 13:jiaf248. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
55. FURMANSKI M, Murcia PR
    Did horses act as intermediate hosts that facilitated the emergence of 1918 pandemic influenza?
    J Infect Dis. 2025 Apr 22:jiaf197. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. CHEN H, Huang X, Wang C, Cowling BJ, et al
    Estimating the waning effectiveness of COVID-19 vaccines from population-level surveillance data in Hong Kong.
    J Infect Dis. 2025 Apr 18:jiaf207. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. CORTIER T, Gilboa M, Layan M, Joseph G, et al
    Factors Associated With the Transmission of the Delta Severe Acute Respiratory Syndrome Coronavirus 2 Variant in Households: The Israeli COVID-19 Family Study (ICoFS).
    J Infect Dis. 2025;231:e734-e742.
    PubMed     Abstract available
    
    
    
58. KOZANLI E, Winkel AMAM, Han AX, van den Brink S, et al
    Shortened SARS-CoV-2 Viral RNA Shedding in Saliva During Early Omicron Compared to Wild-Type Pandemic Phase.
    J Infect Dis. 2025;231:940-945.
    PubMed     Abstract available
    
    
    
59. DOLANGE V, Slamanig S, Abdeljawad A, Lai TY, et al
    A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
    J Infect Dis. 2025;231:e723-e733.
    PubMed     Abstract available
    
    
    
60. ALESSANDRINI J, Smith BT, Fitzpatrick T, Buchan SA, et al
    Socioeconomic Inequities in the Age-Specific Burden of Severe Respiratory Syncytial Virus in Canada, 2016-2019.
    J Infect Dis. 2025;231:e626-e637.
    PubMed     Abstract available
    
    
    
61. JACOBS MB, Clark AE, Goldhaber NH, Valentine HD, et al
    Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population.
    J Infect Dis. 2025;231:921-930.
    PubMed     Abstract available
    
    
    
62. SANKARANARAYANAN R, Ha B, Sun H, Liu K, et al
    Evaluation of Immunoglobulin A Enzyme Immunoassays to Detect Primary Respiratory Syncytial Virus Infection in Infants and Young Children.
    J Infect Dis. 2025;231:1060-1068.
    PubMed     Abstract available
    
    
    
63. CHO HK, Frivold C, Chu HY
    Maternal Immunization.
    J Infect Dis. 2025;231:830-836.
    PubMed     Abstract available
    
    
    
64. CHUN A, Bautista-Castillo A, Osuna I, Nasto K, et al
    Distinguishing Multisystem Inflammatory Syndrome in Children From Typhus Using Artificial Intelligence: MIS-C Versus Endemic Typhus (AI-MET).
    J Infect Dis. 2025;231:931-939.
    PubMed     Abstract available
    
    
    
65. MORRIS SE, Mathis SM, Reeves E, Chung JR, et al
    Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States.
    J Infect Dis. 2025 Apr 12:jiaf061. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. YAMAMOTO S, Mizoue T, Ujiie M, Horii K, et al
    Low levels of post-vaccination hemagglutination inhibition antibodies and their correlation with influenza protection among healthcare workers during the 2024/2025 A/H1N1 outbreak in Japan.
    J Infect Dis. 2025 Apr 10:jiaf183. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. LEWIS NM, Harker EJ, Cleary S, Zhu Y, et al
    Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024.
    J Infect Dis. 2025 Apr 8:jiaf185. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
68. FRUTOS AM, Tenforde MW, Sundaresan D, Naleway AL, et al
    Influenza-associated hospitalization rates by underlying conditions, 2016-17 to 2019-20: A retrospective cohort study.
    J Infect Dis. 2025 Mar 28:jiaf164. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. CAO W, Su W, Song X, Ma L, et al
    Efficacy and Safety of WXSH0208 Tablets in Treatment of Acute Uncomplicated Influenza Infection in Adults: A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Infect Dis. 2025 Mar 25:jiaf075. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. WALSH EE, Peasley M, Branche A, Falsey AR, et al
    Respiratory Syncytial Virus (RSV) Humoral Antibody Responses in Older Adults after Vaccination or Infection.
    J Infect Dis. 2025 Mar 24:jiaf149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. ROSTAD CA, Campbell JD, Paulsen GC, Schnyder Ghamloush S, et al
    Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.
    J Infect Dis. 2025 Mar 22:jiaf144. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. WONG JY, Cheung JK, Presanis AM, De Angelis D, et al
    Assessing the impact of influenza epidemics in Hong Kong.
    J Infect Dis. 2025 Mar 19:jiaf140. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. QUACH HQ, Goergen KM, Grill DE, Ovsyannikova IG, et al
    IL-8 as a Causal Link Between Aging and Impaired Influenza Antibody Responses in Older Adults.
    J Infect Dis. 2025 Mar 17:jiaf148. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. MENG Y, Lin Y, Xiong W, Lau EHY, et al
    Effective Real-time Transmission Estimations Incorporating Population Viral Load Distributions Amid SARS-CoV-2 Variants and Preexisting Immunity.
    J Infect Dis. 2025;231:684-691.
    PubMed     Abstract available
    
    
    
75. MADHI SA, Simoes EAF, Acevedo A, Novoa Pizarro JM, et al
    A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
    J Infect Dis. 2025;231:e478-e487.
    PubMed     Abstract available
    
    
    
76. THAMBI N, Phuah JY, Staupe RP, Tobias LM, et al
    Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150.
    J Infect Dis. 2025;231:e488-e496.
    PubMed     Abstract available
    
    
    
77. PROBOSTE T, Bista D, Clark NJ, Arora S, et al
    Ascertainment of Community Exposure Sites to Ross River Virus During the 2020 Outbreak in Brisbane, Australia.
    J Infect Dis. 2025;231:e501-e510.
    PubMed     Abstract available
    
    
    
78. WINKEL AMAM, Kozanli E, Haverkort ME, Euser SM, et al
    Lower Levels of Household Transmission of SARS-CoV-2 Omicron Variant of Concern vs Wild Type: An Interplay Between Transmissibility and Immune Status.
    J Infect Dis. 2025;231:653-664.
    PubMed     Abstract available
    
    
    
79. REILLY C, Mylonakis E, Dewar R, Young B, et al
    Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019.
    J Infect Dis. 2025;231:677-683.
    PubMed     Abstract available
    
    
    
80. MONTO AS, Foster-Tucker JE, Callear AP, Leis AM, et al
    Respiratory Viral Infections From 2015 to 2022 in the HIVE Cohort of American Households: Incidence, Illness Characteristics, and Seasonality.
    J Infect Dis. 2025;231:795-804.
    PubMed     Abstract available
    
    
    
81. HEDBERG P, van der Werff SD, Naucler P
    The effect of COVID-19 vaccination on the risk of persistent post COVID-19 condition: Cohort study.
    J Infect Dis. 2025 Mar 12:jiaf133. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. VILLALOBOS RODRIGUEZ AP, Wellington Perkins I, Moosavi S, de la Garza A, et al
    Pandemic Preparedness: Analyzing National Plans for Respiratory Pathogen Pandemics in the Americas Region.
    J Infect Dis. 2025;231.
    PubMed     Abstract available
    
    
    
83. REDONDO-BRAVO L, Zureick K, Voto C, Molina Avendano X, et al
    A Comparative Analysis of Universal and Sentinel Surveillance Data for Coronavirus Disease 2019: Insights From Argentina, Chile, and Mexico (2020-2022).
    J Infect Dis. 2025;231.
    PubMed     Abstract available
    
    
    
84. RODRIGUEZ A, Couto P, Acevedo A, Herrera BA, et al
    Strengthening the Surveillance and Response to Public Health Events With a One Health Approach: A Perspective From 12 Countries in Latin America and the Caribbean.
    J Infect Dis. 2025;231.
    PubMed     Abstract available
    
    
    February 2025
85. HUANG QS, Wood T, Aminisani N, Kvalsvig A, et al
    Comparison of the incidence and risk factors of COVID-19 and influenza associated acute respiratory illnesses: Results of the SHIVERS-II, III, IV prospective community cohort study.
    J Infect Dis. 2025 Feb 24:jiaf097. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. LEVENE RE, DeVincenzo J, Conery AL, Ahmad A, et al
    EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.
    J Infect Dis. 2025;231:e290-e298.
    PubMed     Abstract available
    
    
    
87. 
    Correction to: An Update on Highly Pathogenic Avian Influenza A(H5N1) Virus, Clade 2.3.4.4b.
    J Infect Dis. 2025 Feb 17:jiaf085. doi: 10.1093.
    PubMed    
    
    
    
88. GUEZALA MC, Schilling MA
    One Health Networks for Infectious Diseases Surveillance and Pandemic Preparedness in Central and South America.
    J Infect Dis. 2025;231.
    PubMed     Abstract available
    
    
    
89. SOTO G, Romero C, Gonzales M, La Rosa S, et al
    Influenza Virus Surveillance in Healthcare Personnel in Peru: NAMRU SOUTH Experience and Perspective.
    J Infect Dis. 2025;231.
    PubMed     Abstract available
    
    
    
90. LORENZ N, James A, Van Rooyen T, Paterson A, et al
    Decline of Antibodies to Major Viral and Bacterial Respiratory Pathogens During the COVID-19 Pandemic.
    J Infect Dis. 2025;231:e77-e81.
    PubMed     Abstract available
    
    
    
91. CHEW KW, McGinley B, Moser C, Li JZ, et al
    Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.
    J Infect Dis. 2025;231:131-136.
    PubMed     Abstract available
    
    
    
92. BONOMO EJ, Shah M
    Rights-Based Legal Considerations for Tuberculosis Isolation Practices in Community Settings in the Postpandemic Era.
    J Infect Dis. 2025;231:31-36.
    PubMed     Abstract available
    
    
    
93. PISANIC N, Antar AAR, Hetrich MK, Demko ZO, et al
    Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution.
    J Infect Dis. 2025;231:121-130.
    PubMed     Abstract available
    
    
    
94. NAIR MS, Luck MI, Huang Y, Sabo Y, et al
    Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro.
    J Infect Dis. 2025;231:e68-e76.
    PubMed     Abstract available
    
    
    
95. BARZAGHI F, Visconti C, Pipitone GB, Bondesan S, et al
    Severe West Nile Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections in a Patient With Thymoma and Anti-Type I Interferon Antibodies.
    J Infect Dis. 2025;231:e206-e212.
    PubMed     Abstract available
    
    
    
96. GOYA S, Wendm ST, Xie H, Nguyen TV, et al
    Genomic Epidemiology and Evolution of Rhinovirus in Western Washington State, 2021-2022.
    J Infect Dis. 2025;231:e154-e164.
    PubMed     Abstract available
    
    
    
97. JARA JH, Loayza S, Nogareda F, Couto P, et al
    Influenza vaccine averted illnesses in Chile, Guyana, and Paraguay during 2013-2018: a standardized approach to assess value of vaccination.
    J Infect Dis. 2025 Feb 1:jiaf038. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. DESCALZO MA, de Paula Junior FJ, Mallegas NV, Penayo E, et al
    Annual estimation of seasonal influenza burden in six South American countries: a retrospective analysis of SARInet surveillance data to inform policies.
    J Infect Dis. 2025 Feb 1:jiaf037. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
99. CHALKIAS S, Pragalos A, Akinsola A, Berman G, et al
    Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain andN-Terminal Domain mRNA Vaccine.
    J Infect Dis. 2025 Jan 10:jiaf022. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. KOIRALA A, Smith K, Britton PN, Howard-Jones AR, et al
     Protracted Tuberculosis Outbreak in a Pasifika Diaspora in Western Sydney, Australia: The Importance of Community Engagement.
     J Infect Dis. 2025 Jan 9:jiae619. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. BILLINGS WZ, Ge Y, Knight JH, Hemme H, et al
     High dose inactivated influenza vaccine inconsistently improves heterologous antibody responses in an elderly human cohort.
     J Infect Dis. 2025 Jan 8:jiaf003. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. FELDSTEIN LR, Ruffin J, Wiegand RE, Borkowf CB, et al
     Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States.
     J Infect Dis. 2025 Jan 8:jiaf007. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2024
103. ANDERSON EJ, Tippett A, Begier E, Gibson T, et al
     Relative Contribution of Diagnostic Testing to the Diagnosis of Respiratory Syncytial Virus in Hospitalized Adults in the United States.
     J Infect Dis. 2024;230:1342-1351.
     PubMed     Abstract available
     
     
     
104. DOTY B, Ghaswalla P, Bohn RL, Stoszek SK, et al
     Incidence of RSV in Adults: A Comprehensive Review of Observational Studies and Critical Gaps in Information.
     J Infect Dis. 2024;230:e1182-e1201.
     PubMed     Abstract available
     
     
     
105. ANDRES C, Perramon-Malavez A, Creus-Costa A, Gatell A, et al
     Respiratory Viral Coinfections in Pediatric Patients in the Primary Care Setting: A Multicenter Prospective Study Within the COPEDICAT Network.
     J Infect Dis. 2024;230:1337-1341.
     PubMed     Abstract available
     
     
     
106. HAMMERTON SM, Billings WZ, Hemme H, Ross TM, et al
     Estimating standard-dose and high-dose Fluzone vaccine efficacies for influenza A based on HAI titers.
     J Infect Dis. 2024 Dec 13:jiae615. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. WANG J, Genberg BL, Feder K, Kirk GD, et al
     Impact of pandemic-induced service disruptions and behavioral changes on HCV and HIV transmission amongst people who inject drugs: a modeling study.
     J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2024
108. KANG HM, Kim HJ, Jung J, Ahn JY, et al
     Natural Boosting and the Immunogenicity of the XBB.1.5 Monovalent Vaccine in the Coronavirus Disease 2019 Endemic Era: A Longitudinal Observational Study.
     J Infect Dis. 2024 Nov 29:jiae536. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. BIDDLE JE, Nguyen HQ, Talbot HK, Rolfes MA, et al
     Asymptomatic and mildly symptomatic influenza virus infections by season --Case-ascertained household transmission studies, United States, 2017-2023.
     J Infect Dis. 2024 Nov 27:jiae591. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. BRANCHE AR, Falsey AR, Finelli L, Walsh EE, et al
     Residency in Long-Term Care Facilities: An Important Risk Factor for Respiratory Syncytial Virus Hospitalization.
     J Infect Dis. 2024;230:e1007-e1011.
     PubMed     Abstract available
     
     
     
111. BLAIR PW, Siddharthan T, Herrera PM, Cui E, et al
     Validation of Lung Ultrasound for Coronavirus Disease 2019 Prognostication in an International Multicenter Cohort Study.
     J Infect Dis. 2024;230:e1092-e1100.
     PubMed     Abstract available
     
     
     
112. CHEW KW, Taiwo BO, Moser C, Daar ES, et al
     Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.
     J Infect Dis. 2024;230:1177-1186.
     PubMed     Abstract available
     
     
     
113. LEVY ME, Chilunda V, Davis RE, Heaton PR, et al
     Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant.
     J Infect Dis. 2024;230:1197-1201.
     PubMed     Abstract available
     
     
     
114. HARDING ER, Wildenbeest JG, Heikkinen T, Dacosta-Urbieta A, et al
     Inconsistent Increase in Age at Respiratory Syncytial Virus Hospitalization of Children Aged <2 Years During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: A Retrospective Multicenter Study in 4 European Countries.
     J Infect Dis. 2024;230:e985-e995.
     PubMed     Abstract available
     
     
     
115. COHEN C, du Plessis M, Martinson N, Moyes J, et al
     A potential platform for future vaccine trials identifies high incidence of symptomatic and asymptomatic influenza infection among children aged 6-23 months in South Africa.
     J Infect Dis. 2024 Nov 14:jiae550. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. MAK J, Khan S, Britton A, Rose S, et al
     Association of mRNA COVID-19 vaccination and reductions in Post-COVID Conditions following SARS-CoV-2 infection in a US prospective cohort of essential workers.
     J Infect Dis. 2024 Nov 13:jiae556. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. YEGOROV S, Brewer A, Cyr L, Ward BJ, et al
     Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children.
     J Infect Dis. 2024 Nov 6:jiae489. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. ALARCON PC, Ulanowicz CJ, Damen MSMA, Eom J, et al
     Obesity uncovers presence of inflammatory lung macrophage subsets with adipose tissue transcriptomic signature in influenza virus infection.
     J Infect Dis. 2024 Nov 4:jiae535. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2024
119. MAVIAN CN, Tagliamonte MS, Bassett M, Alam M, et al
     COVID-19 lineages in a minimally vaccinated island population: Genomic epidemiology of SARS-CoV-2 in Haiti.
     J Infect Dis. 2024 Oct 23:jiae520. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. SANCHEZ-DE PRADA L, Garcia-Concejo A, Tamayo-Velasco A, Martin-Fernandez M, et al
     miRNome Profiling of Extracellular Vesicles in Patients With Severe COVID-19 and Identification of Predictors of Mortality.
     J Infect Dis. 2024;230:901-911.
     PubMed     Abstract available
     
     
     
121. VERGOUWE M, Biemond JJ, van der Straten K, van Pul L, et al
     A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals.
     J Infect Dis. 2024;230:e860-e871.
     PubMed     Abstract available
     
     
     
122. BROOKS KM, Baltrusaitis K, Clarke DF, Nachman S, et al
     Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032.
     J Infect Dis. 2024;230:878-888.
     PubMed     Abstract available
     
     
     
123. FILES MA, Gentles L, Kehoe L, Adler A, et al
     Kinetics and Durability of Antibody and T-Cell Responses to SARS-CoV-2 in Children.
     J Infect Dis. 2024;230:889-900.
     PubMed     Abstract available
     
     
     
124. DINIZ LM, Dias CS, Oliveira MCL, Simoes E Silva AC, et al
     Outcomes of SARS-CoV-2 and Seasonal Viruses Among 2 Million Adults Hospitalized for Severe Acute Respiratory Infection During the COVID-19 Pandemic in Brazil.
     J Infect Dis. 2024;230:868-877.
     PubMed     Abstract available
     
     
     
125. AHTI J, Toivonen L, Ollila H, Ivaska L, et al
     Household Transmission and Clinical Features of Respiratory Tract Infections That Were SARS-CoV-2 Positive and Negative.
     J Infect Dis. 2024;230:e837-e846.
     PubMed     Abstract available
     
     
     
126. CONNOR C, Taylor HA
     The Importance of Including Long COVID Outcomes When Developing Novel Treatments for Acute COVID-19.
     J Infect Dis. 2024;230:789-796.
     PubMed     Abstract available
     
     
     
127. FRANCIS MR, Gidado S, Nuorti JP
     The Risk of SARS-CoV-2 Transmission in Community Indoor Settings: A Systematic Review and Meta-analysis.
     J Infect Dis. 2024;230:e824-e836.
     PubMed     Abstract available
     
     
     
128. ALLEN DM, Reyne MI, Allingham P, Levickas A, et al
     Genomic Analysis and Surveillance of Respiratory Syncytial Virus Using Wastewater-Based Epidemiology.
     J Infect Dis. 2024;230:e895-e904.
     PubMed     Abstract available
     
     
     
129. BABU TM, Jackson LA, El Sahly HM
     Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration.
     J Infect Dis. 2024 Oct 16:jiae504. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. DOBRZYNSKI D, Branche AR, Falsey AR
     Combination seasonal vaccines for influenza, RSV, SARS-CoV-2, and other pathogens.
     J Infect Dis. 2024 Oct 15:jiae507. doi: 10.1093.
     PubMed    
     
     
     
131. HAGER DN, Zhu Y, Sohn I, Stubblefield WB, et al
     Effectiveness of the original monovalent mRNA COVID-19 vaccination series against hospitalization for COVID-19-associated venous thromboembolism.
     J Infect Dis. 2024 Oct 15:jiae502. doi: 10.1093.
     PubMed     Abstract available
     
     
     
132. LU Y, Matuska K, McEvoy R, Izurieta HS, et al
     Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.
     J Infect Dis. 2024 Oct 15:jiae503. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. BUTT AA, Yan P, Abou-Samra AB, Shaikh OS, et al
     COVID-19 Disease Incidence and Severity in Previously Infected Unvaccinated Compared with Previously Uninfected Vaccinated Persons.
     J Infect Dis. 2024 Oct 8:jiae484. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2024
134. MURUGAIAH V, Watson SJ, Cunliffe RF, Temperton NJ, et al
     A transgenic mouse with a humanised B cell repertoire mounts an antibody response to influenza infection and vaccination.
     J Infect Dis. 2024 Sep 24:jiae472. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. BOONYARATANAKORNKIT J, Wang Q, Nader A, Kimball L, et al
     The Effect of Gastrointestinal Graft-Versus-Host Disease and Diarrhea on the Pharmacokinetic Profile of Sotrovimab in Hematopoietic Stem Cell Transplant Recipients.
     J Infect Dis. 2024;230:670-679.
     PubMed     Abstract available
     
     
     
136. NGUYEN HC, Lal KG, Balinsky CA, Hontz RD, et al
     Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023.
     J Infect Dis. 2024;230:645-656.
     PubMed     Abstract available
     
     
     
137. SINGH K, Rubenstein K, Callier V, Shaw-Saliba K, et al
     SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.
     J Infect Dis. 2024;230:624-634.
     PubMed     Abstract available
     
     
     
138. KADOWAKI T, Sasaki A, Matsumoto N, Mitsuhashi T, et al
     Antibody Titers and the Risk of Infection During the SARS-CoV-2 Omicron Phase in Bizen City, Japan.
     J Infect Dis. 2024;230:662-669.
     PubMed     Abstract available
     
     
     
139. NKOLOLA JP, Liu J, Collier AY, Jacob-Dolan C, et al
     High Frequency of Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Sensitive Nucleocapsid Assays.
     J Infect Dis. 2024;230:e601-e604.
     PubMed     Abstract available
     
     
     
140. GOLDING L, Watts AW, Shew J, Vineta Paramo M, et al
     A Novel Anti-nucleocapsid Antibody Avidity Method for Identifying SARS-CoV-2 Reinfections.
     J Infect Dis. 2024;230:e579-e583.
     PubMed     Abstract available
     
     
     
141. FISCHER RJ, Bushmaker T, Williamson BN, Perez-Perez L, et al
     Compartmentalized SARS-CoV-2 Replication in the Upper vs Lower Respiratory Tract After Intranasal Inoculation or Aerosol Exposure.
     J Infect Dis. 2024;230:657-661.
     PubMed     Abstract available
     
     
     
142. LIN LY, Gantner P, Li S, Su B, et al
     Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and SARS-CoV-2 vaccines.
     J Infect Dis. 2024 Sep 20:jiae464. doi: 10.1093.
     PubMed     Abstract available
     
     
     
143. WEBBY RJ, Uyeki TM
     An Update on Highly Pathogenic Avian Influenza A(H5N1) Virus, Clade 2.3.4.4b.
     J Infect Dis. 2024 Sep 16:jiae379. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. BAGDASARIAN N, Wineland N, Callo SL
     Personal Protective Equipment Guidance for Highly Pathogenic Avian Influenza H5N1 Should Be Adapted to Meet the Needs of Dairy Farm Workers.
     J Infect Dis. 2024 Sep 16:jiae380. doi: 10.1093.
     PubMed    
     
     
     
145. BAHAKEL H, Spieker AJ, Hayek H, Schuster JE, et al
     Immunogenicity and Reactogenicity of High-dose or Standard-dose Influenza Vaccine in a Second Consecutive Influenza Season.
     J Infect Dis. 2024 Sep 16:jiae454. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. ONISIFOROU A, Zanos P
     From Viral Infections to Alzheimer's Disease: Unveiling the Mechanistic Links Through Systems Bioinformatics.
     J Infect Dis. 2024;230.
     PubMed     Abstract available
     
     
     
147. TANG Y, Boribong BP, Swank ZN, Demokritou M, et al
     COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA within the oronasopharynx of young children.
     J Infect Dis. 2024 Sep 10:jiae450. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. JANES H, Fisher LH, Kee JJ, Parameswaran L, et al
     Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
     J Infect Dis. 2024 Sep 3:jiae400. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2024
149. ZHANG C, Fang VJ, Chan KH, Leung GM, et al
     Interplay between viral shedding, age, and symptoms on individual infectiousness of influenza cases in households.
     J Infect Dis. 2024 Aug 28:jiae434. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. LEOPOLD L, Vingerhoets J, Deleu S, Nalpas C, et al
     Efficacy and Safety of Pimodivir Combined with Standard-of-care in Hospitalized and Non-hospitalized High-risk Adolescents and Adults with Influenza A Infection.
     J Infect Dis. 2024 Aug 22:jiae408. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. MEIER A, Sakoulas G, Nizet V, Ulloa ER, et al
     Neutrophil Extracellular Traps: An Emerging Therapeutic Target to Improve Infectious Disease Outcomes.
     J Infect Dis. 2024;230:514-521.
     PubMed     Abstract available
     
     
     
152. CHOUDHARY MC, Deo R, Evering TH, Chew KW, et al
     Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
     J Infect Dis. 2024;230:394-402.
     PubMed     Abstract available
     
     
     
153. BORDOY AE, Valles X, Fernandez-Nager J, Sanchez-Roig M, et al
     Analysis of a Large Severe Acute Respiratory Syndrome Coronavirus 2 (Alpha) Outbreak in a Catalan Prison Using Conventional and Genomic Epidemiology.
     J Infect Dis. 2024;230:374-381.
     PubMed     Abstract available
     
     
     
154. KIM AE, Bennett JC, Luiten K, O'Hanlon JA, et al
     Comparative Diagnostic Utility of SARS-CoV-2 Rapid Antigen and Molecular Testing in a Community Setting.
     J Infect Dis. 2024;230:363-373.
     PubMed     Abstract available
     
     
     
155. STONE M, Spencer BR, Warden DE, Fink RV, et al
     Patient and Immunological Factors Associated With Delayed Clearance of Mucosal Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Symptom Persistence.
     J Infect Dis. 2024;230:357-362.
     PubMed     Abstract available
     
     
     
156. CORDERO DA JR
     Persons Deprived of Liberty in the Philippines: A Call to Health Equality.
     J Infect Dis. 2024;230:522-523.
     PubMed    
     
     
     
157. STRUNZ B, Maucourant C, Mehta A, Wan H, et al
     Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19.
     J Infect Dis. 2024;230:e318-e326.
     PubMed     Abstract available
     
     
     
158. ROZNIK K, Andargie TE, Johnston TS, Gordon O, et al
     Emergency Myelopoiesis Distinguishes Multisystem Inflammatory Syndrome in Children From Pediatric Severe Coronavirus Disease 2019.
     J Infect Dis. 2024;230:e305-e317.
     PubMed     Abstract available
     
     
     
159. POLLARD KJ, Traina-Dorge V, Medearis SM, Bosak A, et al
     Respiratory Syncytial Virus Infects Peripheral and Spinal Nerves and Induces Chemokine-Mediated Neuropathy.
     J Infect Dis. 2024;230:467-479.
     PubMed     Abstract available
     
     
     
160. AVERIN A, Law A, Shea K, Atwood M, et al
     Episodic Cost of Lower Respiratory Tract Illness due to Respiratory Syncytial Virus Among US Infants During the First Year of Life.
     J Infect Dis. 2024;230:480-484.
     PubMed     Abstract available
     
     
     
161. CARRICO J, Hicks KA, Wilson E, Panozzo CA, et al
     The Annual Economic Burden of Respiratory Syncytial Virus in Adults in the United States.
     J Infect Dis. 2024;230:e342-e352.
     PubMed     Abstract available
     
     
     
162. GOH YS, Fong SW, Hor PX, Loh CY, et al
     Variant-Specific IgA Protects Against Omicron Infection.
     J Infect Dis. 2024;230:e287-e291.
     PubMed     Abstract available
     
     
     
163. MARCHESE AM, Rousculp M, Macbeth J, Beyhaghi H, et al
     The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.
     J Infect Dis. 2024;230:e496-e502.
     PubMed     Abstract available
     
     
     
164. EGESKOV-CAVLING AM, van Wijhe M, Yakimov V, Johannesen CK, et al
     Genome-wide Association Study of Susceptibility to Respiratory Syncytial Virus Hospitalization in Young Children <5 Years of age.
     J Infect Dis. 2024;230:e333-e341.
     PubMed     Abstract available
     
     
     
165. LEWNARD JA, Hong V, Grant LR, Ackerson BK, et al
     Association of pneumococcal conjugate vaccination with SARS-CoV-2 infection among older adult recipients of COVID-19 vaccines: a longitudinal cohort study.
     J Infect Dis. 2024 Aug 5:jiae387. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2024
166. BEN MAMOUN C, Wormser GP
     Reply to Dow and Smith.
     J Infect Dis. 2024;230:273.
     PubMed    
     
     
     
167. WILLIAMS TC, Marlow R, Hardelid P, Lyttle MD, et al
     Clinical Impact of Serious Respiratory Disease in Children Under the Age of 2 Years During the 2021-2022 Bronchiolitis Season in England, Scotland, and Ireland.
     J Infect Dis. 2024;230:e111-e120.
     PubMed     Abstract available
     
     
     
168. SIDHU JK, Siggins MK, Liew F, Russell CD, et al
     Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.
     J Infect Dis. 2024;230:e17-e29.
     PubMed     Abstract available
     
     
     
169. HARTELOH P, van Mechelen R
     Mortality Rates of the Spanish Flu and Coronavirus Disease 2019 in the Netherlands: A Historical Comparison.
     J Infect Dis. 2024;230:38-44.
     PubMed     Abstract available
     
     
     
170. LIM WW, Feng S, Wong SS, Sullivan SG, et al
     Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.
     J Infect Dis. 2024;230:152-160.
     PubMed     Abstract available
     
     
     
171. TEHRANI ZR, Habibzadeh P, Flinko R, Chen H, et al
     Deficient Generation of Spike-Specific Long-Lived Plasma Cells in the Bone Marrow After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
     J Infect Dis. 2024;230:e30-e33.
     PubMed     Abstract available
     
     
     
172. ZHENG X, Lu R, Pan D, Peng L, et al
     Regulatory T and CXCR3+ Circulating Tfh Cells Concordantly Shape the Neutralizing Antibody Responses in Individuals Who Have Recovered from Mild COVID-19.
     J Infect Dis. 2024;230:28-37.
     PubMed     Abstract available
     
     
     
173. SCHWARZ TF, Hwang SJ, Ylisastigui P, Liu CS, et al
     Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
     J Infect Dis. 2024;230:e102-e110.
     PubMed     Abstract available
     
     
     
174. TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al
     Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023.
     J Infect Dis. 2024;230:141-151.
     PubMed     Abstract available
     
     
     
175. SUMNER KM, Yadav R, Noble EK, Sandford R, et al
     Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022.
     J Infect Dis. 2024;230:45-54.
     PubMed     Abstract available
     
     
     
176. LEDDEROSE C, Valsami EA, Elevado M, Junger WG, et al
     Adenosine Triphosphate Release From Influenza-Infected Lungs Enhances Neutrophil Activation and Promotes Disease Progression.
     J Infect Dis. 2024;230:120-130.
     PubMed     Abstract available
     
     
     
177. FELL DB, Russell M, Fung SG, Swayze S, et al
     Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada.
     J Infect Dis. 2024;230:e80-e92.
     PubMed     Abstract available
     
     
     
178. BENNETT C, Rivers EJ, Woo W, Bloch M, et al
     Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
     J Infect Dis. 2024;230:e4-e16.
     PubMed     Abstract available
     
     
     
179. TERSTAPPEN J, Delemarre EM, Versnel A, White JT, et al
     RSV Neutralizing Antibodies in Dried Blood.
     J Infect Dis. 2024;230:e93-e101.
     PubMed     Abstract available
     
     
     
180. LEE K, Williams KV, Englund JA, Sullivan SG, et al
     The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the Northern Hemisphere: A Retrospective Modeling Study in the United States.
     J Infect Dis. 2024;230:131-140.
     PubMed     Abstract available
     
     
     
181. CHONG EA, Kumashie KG, Chong ER, Fabrizio J, et al
     Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.
     J Infect Dis. 2024;230:15-27.
     PubMed     Abstract available
     
     
     
182. LIN J, Bai S, He L, Yang Y, et al
     Cytotoxic Lymphocyte-Monocyte Complex Reflects the Dynamics of Coronavirus Disease 2019 Systemic Immune Response.
     J Infect Dis. 2024;230:5-14.
     PubMed     Abstract available
     
     
     
183. BLOOM N, Ramirez SI, Cohn H, Parikh UM, et al
     SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback.
     J Infect Dis. 2024 Jul 22:jiae371. doi: 10.1093.
     PubMed     Abstract available
     
     
     
184. HILL-BATORSKI L, Weiner JA, Ackerman ME, Hatta Y, et al
     Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults.
     J Infect Dis. 2024 Jul 16:jiae361. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. AGRAWAL P, Giron LB, Singh S, Haw NJ, et al
     Pre-pandemic Metabolic Correlates of COVID-19 Severity and Long COVID Incidence in People Living with HIV.
     J Infect Dis. 2024 Jul 16:jiae362. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. CHIME N, Anspach B, Jain V, Laajalahti O, et al
     Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV.
     J Infect Dis. 2024 Jul 5:jiae342. doi: 10.1093.
     PubMed     Abstract available
     
     
     
187. MCCARRON M, Yau TS, Griffin C, Marcenac P, et al
     Do pregnant persons want influenza vaccines? Knowledge, attitudes, perceptions, and practices toward influenza vaccines in 8 low- and middle-income countries.
     J Infect Dis. 2024 Jul 2:jiae340. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
188. ANANWORANICH J, Lee IT, Ensz D, Carmona L, et al
     Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial.
     J Infect Dis. 2024 Jun 27:jiae329. doi: 10.1093.
     PubMed     Abstract available
     
     
     
189. GOSWAMI J, Baqui AH, Doreski PA, Perez Marc G, et al
     Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.
     J Infect Dis. 2024 Jun 18:jiae316. doi: 10.1093.
     PubMed     Abstract available
     
     
     
190. ATTUR M, Petrilli C, Adhikari S, Iturrate E, et al
     Interleukin-1 Receptor Antagonist Gene (IL1RN) Variants Modulate the Cytokine Release Syndrome and Mortality of COVID-19.
     J Infect Dis. 2024;229:1740-1749.
     PubMed     Abstract available
     
     
     
191. HARTELOH P, van Mechelen R
     Reply to Mattiuzzi and Lippi.
     J Infect Dis. 2024;229:1930.
     PubMed    
     
     
     
192. MATTIUZZI C, Lippi G
     Historical Comparison Between the Death Rate for Spanish Flu and Coronavirus Disease 2019 in Italy.
     J Infect Dis. 2024;229:1928-1929.
     PubMed    
     
     
     
193. GAY L, Rouviere MS, Mezouar S, Richaud M, et al
     Vgamma9Vdelta2 T-cells Are Potent Inhibitors of SARS-CoV-2 Replication and Represent Effector Phenotypes in Patients With COVID-19.
     J Infect Dis. 2024;229:1759-1769.
     PubMed     Abstract available
     
     
     
194. IVERSEN KK, Ronit A, Ahlstrom MG, Nordestgaard BG, et al
     Lung Function Trajectories in Mild COVID-19 With 2-year Follow-up.
     J Infect Dis. 2024;229:1750-1758.
     PubMed     Abstract available
     
     
     
195. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
     Hybrid Immunity to SARS-CoV-2 During Pregnancy Provides More Durable Infant Antibody Responses Compared to Natural Infection Alone.
     J Infect Dis. 2024;229:1728-1739.
     PubMed     Abstract available
     
     
     
196. LIM SY, Kim JW, Kim JY, Kang SW, et al
     The Association Between Antibody Responses and Prolonged Viable Severe Acute Respiratory Syndrome Coronavirus 2 Shedding in Immunocompromised Patients: A Prospective Cohort Study.
     J Infect Dis. 2024;229:1722-1727.
     PubMed     Abstract available
     
     
     
197. AMSTUTZ A, Chammartin F, Audige A, Eichenberger AL, et al
     Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).
     J Infect Dis. 2024 Jun 7:jiae291. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
198. TOWNSEND L, Gillespie P, McGrath J, Kenny C, et al
     Health Care Personnel Workdays Lost and Direct Health Care Salary Costs Incurred due to COVID-19 Infection in the Age of Widespread Vaccine Availability.
     J Infect Dis. 2024 May 21:jiae223. doi: 10.1093.
     PubMed     Abstract available
     
     
     
199. BEN MAMOUN C, Vydyam P
     Response to the Letter by Liu and Colleagues.
     J Infect Dis. 2024;229:1601.
     PubMed    
     
     
     
200. FOTOOH ABADI L, Sharma MB, Kelesidis T
     Single-Cell Profiling of the Differential In Vivo Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Lung Tissue Cell Subtypes at the Protein Level.
     J Infect Dis. 2024;229:1382-1386.
     PubMed     Abstract available
     
     
     
201. WONG M, Gain C, Sharma MB, Fotooh Abadi L, et al
     Severe Acute Respiratory Syndrome Coronavirus 2 Infection Alters Mediators of Lung Tissue Remodeling In Vitro and In Vivo.
     J Infect Dis. 2024;229:1372-1381.
     PubMed     Abstract available
     
     
     
202. DOS RAMOS ALMEIDA CJL, Veras FP, Paiva IM, Schneider AH, et al
     Neutrophil Virucidal Activity Against SARS-CoV-2 Is Mediated by Neutrophil Extracellular Traps.
     J Infect Dis. 2024;229:1352-1365.
     PubMed     Abstract available
     
     
     
203. LEDUCQ V, Zafilaza K, Fauchois A, Ghidaoui E, et al
     Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies.
     J Infect Dis. 2024;229:1341-1351.
     PubMed     Abstract available
     
     
     
204. MOTSOENENG BM, Dhar N, Nunes MC, Krammer F, et al
     Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women.
     J Infect Dis. 2024 May 14:jiae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
205. SMITH CL, Didion E, Aung H, Tamilselvan B, et al
     Longitudinal analysis of nursing home residents' T cell responses after SARS-CoV-2 mRNA vaccinations shows influence of biological sex and SARS-CoV-2 infection history.
     J Infect Dis. 2024 May 14:jiae234. doi: 10.1093.
     PubMed     Abstract available
     
     
     
206. HOY G, Stadlbauer D, Balmaseda A, Kuan G, et al
     Humoral correlates of protection against influenza A H3N2 virus infection.
     J Infect Dis. 2024 May 9:jiae258. doi: 10.1093.
     PubMed     Abstract available
     
     
     
207. EBINGER JE, Sun N, Joung SY, Sanchez JMS, et al
     Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following Prior Infection or Vaccination.
     J Infect Dis. 2024 May 8:jiae130. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
208. BI Q, Dickerman BA, Nguyen HQ, Martin ET, et al
     Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection.
     J Infect Dis. 2024 Apr 30:jiae220. doi: 10.1093.
     PubMed     Abstract available
     
     
     
209. JUHL AK, Lokso Dietz L, Schmeltz Sogaard O, Reekie J, et al
     Longitudinal evaluation of SARS-CoV-2 T cell immunity over 2 years following vaccination and infection.
     J Infect Dis. 2024 Apr 30:jiae215. doi: 10.1093.
     PubMed     Abstract available
     
     
     
210. MORO RN, Mehaffy C, De P, Phillips E, et al
     Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-like Reactions During Treatment of Latent Tuberculosis Infection.
     J Infect Dis. 2024 Apr 19:jiae180. doi: 10.1093.
     PubMed     Abstract available
     
     
     
211. ZAMA D, Zanaroli A, Corbelli A, Lo Vecchio A, et al
     SARS-CoV-2 Infection in the Pediatric Oncology Population: The Definitive Comprehensive Report of the Infectious Diseases Working Group of AIEOP.
     J Infect Dis. 2024;229:1050-1058.
     PubMed     Abstract available
     
     
     
212. GUILBAUD R, Franco Yusti AM, Leducq V, Zafilaza K, et al
     Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients: A Retrospective Case-Control Study.
     J Infect Dis. 2024;229:1041-1049.
     PubMed     Abstract available
     
     
     
213. SIMOES EAF, Botteman M, Chirikov V
     Epidemiology of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection in Japanese Children, 2011-2017.
     J Infect Dis. 2024;229:1112-1122.
     PubMed     Abstract available
     
     
     
214. WALSH EE, Falsey AR, Zareba AM, Jiang Q, et al
     Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
     J Infect Dis. 2024 Apr 12:jiae185. doi: 10.1093.
     PubMed     Abstract available
     
     
     
215. BARTSCH SM, O'Shea KJ, Weatherwax C, Strych U, et al
     What is the economic benefit of annual COVID-19 vaccination from the adult individual perspective?
     J Infect Dis. 2024 Apr 6:jiae179. doi: 10.1093.
     PubMed     Abstract available
     
     
     
216. RECTO C, Fourati S, Khellaf M, Pawlotsky JM, et al
     Respiratory syncytial virus vs. Influenza virus infection: mortality and morbidity comparison over 7 epidemic seasons in an elderly population.
     J Infect Dis. 2024 Apr 4:jiae171. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
217. FIGUEROA AL, Azzi JR, Eghtesad B, Priddy F, et al
     Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ Transplant Recipients.
     J Infect Dis. 2024 Mar 21:jiae140. doi: 10.1093.
     PubMed     Abstract available
     
     
     
218. FINSTERER J
     Cerebrospinal Fluid Biomarkers of Neuronal/Glial Damage or Immune Activation Are Unsuitable for Assessing Post-COVID Cognitive Impairment.
     J Infect Dis. 2024;229:918-919.
     PubMed    
     
     
     
219. ROSSLER A, Knabl L, Netzl A, Bante D, et al
     Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
     J Infect Dis. 2024;229:644-647.
     PubMed     Abstract available
     
     
     
220. LI X, Zhou G, Sun X, Qu S, et al
     NLRP12 Senses the SARS-CoV-2 Membrane Protein and Promotes an Inflammatory Response.
     J Infect Dis. 2024;229:660-670.
     PubMed     Abstract available
     
     
     
221. JENSEN TO, Grandits GA, Jain MK, Murray TA, et al
     Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
     J Infect Dis. 2024;229:671-679.
     PubMed     Abstract available
     
     
     
222. BAY P, Loegel C, Ly A, Soulier A, et al
     Clinical Phenotypes and Molecular Characteristics of Respiratory Syncytial Virus in Adults: A Monocentric Prospective Study Between 2019 and 2022.
     J Infect Dis. 2024;229:728-732.
     PubMed     Abstract available
     
     
     
223. ALI YM, Carnell GW, Fumagalli S, Mercurio D, et al
     Inhibition of the Lectin Pathway of Complement Activation Reduces Acute Respiratory Distress Syndrome Severity in a Mouse Model of SARS-CoV-2 Infection.
     J Infect Dis. 2024;229:680-690.
     PubMed     Abstract available
     
     
     
224. SCOTT N, Martinovich KM, Granland CM, Seppanen EJ, et al
     Nasal Delivery of Haemophilus haemolyticus Is Safe, Reduces Influenza Severity, and Prevents Development of Otitis Media in Mice.
     J Infect Dis. 2024 Mar 12:jiae069. doi: 10.1093.
     PubMed     Abstract available
     
     
     
225. SEPULVEDA-PACHON IT, Dunne EM, Hanquet G, Baay M, et al
     Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review.
     J Infect Dis. 2024 Mar 11:jiae125. doi: 10.1093.
     PubMed     Abstract available
     
     
     
226. LIM WW, Shuo F, Wong SS, Sullivan SG, et al
     Hemagglutination inhibition antibody titers mediate influenza vaccine efficacy against symptomatic influenza A(H1N1), A(H3N2), and B/Victoria infections.
     J Infect Dis. 2024 Mar 7:jiae122. doi: 10.1093.
     PubMed     Abstract available
     
     
     
227. HAK SF, Venekamp RP, Billard MN, van Houten MA, et al
     Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
228. JOHNSON M, Chelysheva I, Oner D, McGinley J, et al
     A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
229. OSEI-YEBOAH R, Johannesen CK, Egeskov-Cavling AM, Chen J, et al
     Respiratory Syncytial Virus-Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
230. CHAPPIN K, Besteman SB, Hennus MP, Wildenbeest JG, et al
     Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
231. VAN ROEKEL C, Poukka E, Turunen T, Nohynek H, et al
     Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
232. KENMOE S, Chu HY, Dawood FS, Milucky J, et al
     Burden of Respiratory Syncytial Virus-Associated Acute Respiratory Infections During Pregnancy.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
233. OSEI-YEBOAH R, Zhu F, Wang X, Nair H, et al
     Respiratory Syncytial Virus-Associated Hospital Admissions by Deprivation Levels Among Children and Adults in Scotland.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
234. SHEIKH Z, Potter E, Li Y, Cohen RA, et al
     Validity of Clinical Severity Scores for Respiratory Syncytial Virus: A Systematic Review.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
235. EGESKOV-CAVLING AM, Johannesen CK, Lindegaard B, Fischer TK, et al
     Underreporting and Misclassification of Respiratory Syncytial Virus-Coded Hospitalization Among Adults in Denmark Between 2015-2016 and 2017-2018.
     J Infect Dis. 2024;229.
     PubMed     Abstract available
     
     
     
236. ASLANIKASHVILI A, Rylander C, Manjavidze T, Gamkrelidze A, et al
     Relationship between hepatitis C infection and treatment status and COVID-19-related hospitalizations in Georgia.
     J Infect Dis. 2024 Mar 1:jiae103. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
237. SHAW CA, Essink B, Harper C, Mithani R, et al
     Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase I Clinical Trial in Healthy Older Adults.
     J Infect Dis. 2024 Feb 22:jiae081. doi: 10.1093.
     PubMed     Abstract available
     
     
     
238. CASADEVALL A, Sullivan DJ
     Late Administration and Corticosteroid Usage Explain Inefficacy in COVID-19 Convalescent Plasma Trial.
     J Infect Dis. 2024;229:617-618.
     PubMed    
     
     
     
239. KANBERG N, Grahn A, Stentoft E, Bremell D, et al
     COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients With Neurocognitive Post-COVID Complications.
     J Infect Dis. 2024;229:493-501.
     PubMed     Abstract available
     
     
     
240. YOUNG BR, Ho F, Lin Y, Lau EHY, et al
     Estimation of the Time-Varying Effective Reproductive Number of COVID-19 Based on Multivariate Time Series of Severe Health Outcomes.
     J Infect Dis. 2024;229:502-506.
     PubMed     Abstract available
     
     
     
241. VUJKOVIC A, Ha M, de Block T, van Petersen L, et al
     Diagnosing Viral Infections Through T-Cell Receptor Sequencing of Activated CD8+ T Cells.
     J Infect Dis. 2024;229:507-516.
     PubMed     Abstract available
     
     
     
242. MONROE JM, Quach HQ, Punia S, Enninga EAL, et al
     Vertical Transmission of SARS-CoV-2-Specific Antibodies and Cytokine Profiles in Pregnancy.
     J Infect Dis. 2024;229:473-484.
     PubMed     Abstract available
     
     
     
243. HEIMONEN J, Chow EJ, Wang Y, Hughes JP, et al
     Risk of Subsequent Respiratory Virus Detection After Primary Virus Detection in a Community Household Study-King County, Washington, 2019-2021.
     J Infect Dis. 2024;229:422-431.
     PubMed     Abstract available
     
     
     
244. MAKHSOUS N, Goya S, Avendano CC, Rupp J, et al
     Within-Host Rhinovirus Evolution in Upper and Lower Respiratory Tract Highlights Capsid Variability and Mutation-Independent Compartmentalization.
     J Infect Dis. 2024;229:403-412.
     PubMed     Abstract available
     
     
     
245. AMINISANI N, Wood T, Jelley L, Wong C, et al
     The burden of HMPV and influenza associated hospitalizations in adults in New Zealand, 2012-2015.
     J Infect Dis. 2024 Feb 13:jiae064. doi: 10.1093.
     PubMed     Abstract available
     
     
     
246. CHALKIAS S, McGhee N, Whatley JL, Essink B, et al
     Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
     J Infect Dis. 2024 Feb 13:jiae067. doi: 10.1093.
     PubMed     Abstract available
     
     
     
247. MUNOZ-QUILES C, Lopez-Lacort M, Urchueguia A, Diez-Domingo J, et al
     Risk of cardiovascular events after influenza: A population-based Self Controlled Case Series study, Spain 2011-2018.
     J Infect Dis. 2024 Feb 8:jiae070. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2024
248. SHAW CA, Mithani R, Kapoor A, Dhar R, et al
     Safety, Tolerability and Immunogenicity of a mRNA-based RSV Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.
     J Infect Dis. 2024 Jan 31:jiae035. doi: 10.1093.
     PubMed     Abstract available
     
     
     
249. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
     Hybrid immunity to SARS-CoV-2 during pregnancy provides more durable infant antibody responses compared to natural infection or vaccination alone.
     J Infect Dis. 2024 Jan 29:jiae046. doi: 10.1093.
     PubMed    
     
     
     
250. ABELA IA, Hauser A, Schwarzmuller M, Pasin C, et al
     Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study.
     J Infect Dis. 2024 Jan 16:jiae002. doi: 10.1093.
     PubMed     Abstract available
     
     
     
251. HEDBERG P, Naucler P
     Post-COVID-19 Condition After SARS-CoV-2 Infections During the Omicron Surge vs the Delta, Alpha, and Wild Type Periods in Stockholm, Sweden.
     J Infect Dis. 2024;229:133-136.
     PubMed     Abstract available
     
     
     
252. WEI SC, Freeman D, Himschoot A, Clarke KEN, et al
     Who Gets Sick From COVID-19? Sociodemographic Correlates of Severe Adult Health Outcomes During Alpha- and Delta-Variant Predominant Periods: September 2020-November 2021.
     J Infect Dis. 2024;229:122-132.
     PubMed     Abstract available
     
     
     
253. SULLIVAN T
     Lessons (Machine) Learned From COVID-19.
     J Infect Dis. 2024;229:7-9.
     PubMed     Abstract available
     
     
     
254. CARROLL TD, Wong T, Morris MK, Di Germanio C, et al
     Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters.
     J Infect Dis. 2024 Jan 12:jiad568. doi: 10.1093.
     PubMed     Abstract available
     
     
     
255. HOWARD LM, Jensen TL, Goll JB, Gelber CE, et al
     Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients.
     J Infect Dis. 2024 Jan 5:jiad611. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2023
256. SAJKOV D, Woodman R, Honda-Okubo Y, Barbara J, et al
     A Multi-Season Randomised Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants with Chronic Disease or Older Age.
     J Infect Dis. 2023 Dec 29:jiad589. doi: 10.1093.
     PubMed     Abstract available
     
     
     
257. ZHANG Y, Zhou Y, Chen J, Wu J, et al
     Vaccination Shapes Within-Host SARS-CoV-2 Diversity of Omicron BA.2.2 Breakthrough Infection.
     J Infect Dis. 2023 Dec 27:jiad572. doi: 10.1093.
     PubMed     Abstract available
     
     
     
258. WIDAGDO W, Bastian AR, Jastorff AM, Scheys I, et al
     Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-dose Influenza Vaccine in Adults 65 Years and Older: a Noninferiority Trial.
     J Infect Dis. 2023 Dec 22:jiad594. doi: 10.1093.
     PubMed     Abstract available
     
     
     
259. HERMIDA N, Ferguson M, Leroux-Roels I, Pagnussat S, et al
     Safety and Immunogenicity of Respiratory Syncytial Virus Pre-fusion Maternal Vaccine Co-administered with Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
     J Infect Dis. 2023 Dec 22:jiad560. doi: 10.1093.
     PubMed     Abstract available
     
     
     
260. YAMAMOTO S, Matsuda K, Maeda K, Horii K, et al
     Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
     J Infect Dis. 2023;228:1652-1661.
     PubMed     Abstract available
     
     
     
261. PENETRA SLS, Santos HFP, Resende PC, Bastos LS, et al
     SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.
     J Infect Dis. 2023;228:1680-1689.
     PubMed     Abstract available
     
     
     
262. CHENE A, Desrames A, Tomlinson A, Ruffie C, et al
     An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti-Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike.
     J Infect Dis. 2023;228:1675-1679.
     PubMed     Abstract available
     
     
     
263. HUH K, Kang M, Kim YE, Choi Y, et al
     Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients.
     J Infect Dis. 2023 Dec 14:jiad501. doi: 10.1093.
     PubMed     Abstract available
     
     
     
264. WEST AC, Harpur CM, Le Page MA, Lam M, et al
     Harnessing endogenous peptide compounds as potential therapeutics for severe influenza.
     J Infect Dis. 2023 Dec 7:jiad566. doi: 10.1093.
     PubMed     Abstract available
     
     
     
265. TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al
     Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023.
     J Infect Dis. 2023 Dec 2:jiad542. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2023
266. TUTTLE DJ, Castanha PMS, Nasser A, Wilkins MS, et al
     SARS-CoV-2 mRNA vaccines induce greater complement activation and decreased viremia and Nef antibodies in men with HIV-1.
     J Infect Dis. 2023 Nov 30:jiad544. doi: 10.1093.
     PubMed     Abstract available
     
     
     
267. FELL DB, Russell M, Fung SG, Swayze S, et al
     Effectiveness of maternal influenza vaccination during pregnancy against laboratory-confirmed seasonal influenza among infants under 6 months of age in Ontario, Canada.
     J Infect Dis. 2023 Nov 29:jiad539. doi: 10.1093.
     PubMed     Abstract available
     
     
     
268. LEE K, Williams KV, Englund JA, Sullivan SG, et al
     The potential benefits of delaying seasonal influenza vaccine selections for the Northern Hemisphere: a retrospective modeling study in the United States.
     J Infect Dis. 2023 Nov 29:jiad541. doi: 10.1093.
     PubMed     Abstract available
     
     
     
269. KARABA AH, Morgenlander WR, Johnston TS, Hage C, et al
     Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls.
     J Infect Dis. 2023 Nov 29:jiad534. doi: 10.1093.
     PubMed     Abstract available
     
     
     
270. FRANKLIN A, John TM, Khawaja F, Jiang Y, et al
     Utility of Bronchoalveolar Lavage for the Diagnosis and Management of COVID-19 in Patients With Cancer.
     J Infect Dis. 2023;228:1549-1558.
     PubMed     Abstract available
     
     
     
271. ERNST T, Ryan MC, Liang HJ, Wang JP, et al
     Neuronal and Glial Metabolite Abnormalities in Participants With Persistent Neuropsychiatric Symptoms After COVID-19: A Brain Proton Magnetic Resonance Spectroscopy Study.
     J Infect Dis. 2023;228:1559-1570.
     PubMed     Abstract available
     
     
     
272. ONWUCHEKWA C, Atwell J, Moreo LM, Menon S, et al
     Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis.
     J Infect Dis. 2023;228:1516-1527.
     PubMed     Abstract available
     
     
     
273. OSEI-YEBOAH R, Spreeuwenberg P, Del Riccio M, Fischer TK, et al
     Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union.
     J Infect Dis. 2023;228:1539-1548.
     PubMed     Abstract available
     
     
     
274. DEL RICCIO M, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, et al
     Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years.
     J Infect Dis. 2023;228:1528-1538.
     PubMed     Abstract available
     
     
     
275. LU X, Liu F, Tzeng WP, York IA, et al
     Antibody-mediated Suppression Regulates the Humoral Immune Response to Influenza Vaccination in Humans.
     J Infect Dis. 2023 Nov 20:jiad493. doi: 10.1093.
     PubMed     Abstract available
     
     
     
276. JI W, Guthmiller J
     Goldilocks zone of preexisting immunity: too little or too much suppresses diverse antibody responses against influenza viruses.
     J Infect Dis. 2023 Nov 18:jiad494. doi: 10.1093.
     PubMed     Abstract available
     
     
     
277. HAIDAR G, Hodges JC, Bilderback A, Lukanski A, et al
     Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.
     J Infect Dis. 2023 Nov 16:jiad511. doi: 10.1093.
     PubMed     Abstract available
     
     
     
278. MORI M, Doi T, Murata M, Moriyama Y, et al
     Impact of nutritional status on antibody titer after booster mRNA COVID-19 vaccine among elderly adults in Japan.
     J Infect Dis. 2023 Nov 14:jiad495. doi: 10.1093.
     PubMed     Abstract available
     
     
     
279. LASRADO N, Barouch DH
     SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds.
     J Infect Dis. 2023;228:1311-1313.
     PubMed     Abstract available
     
     
     
280. LOWENSTEYN YN, Zheng Z, Rave N, Bannier MAGE, et al
     Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study.
     J Infect Dis. 2023;228:1394-1399.
     PubMed     Abstract available
     
     
     
281. JITTAMALA P, Schilling WHK, Watson JA, Luvira V, et al
     Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV).
     J Infect Dis. 2023;228:1318-1325.
     PubMed     Abstract available
     
     
     
282. KYO M, Zhu Z, Shibata R, Fujiogi M, et al
     Respiratory Virus-Specific Nasopharyngeal Lipidome Signatures and Severity in Infants With Bronchiolitis: A Prospective Multicenter Study.
     J Infect Dis. 2023;228:1410-1420.
     PubMed     Abstract available
     
     
     
283. NAKAJO K, Nishiura H
     Age-Dependent Risk of Respiratory Syncytial Virus Infection: A Systematic Review and Hazard Modeling From Serological Data.
     J Infect Dis. 2023;228:1400-1409.
     PubMed     Abstract available
     
     
     
284. ZHONG S, Ng TWY, Skowronski DM, Iuliano AD, et al
     Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody response by prior season's vaccine status.
     J Infect Dis. 2023 Nov 10:jiad497. doi: 10.1093.
     PubMed     Abstract available
     
     
     
285. HEDSKOG C, Rodriguez L, Roychoudhury P, Huang ML, et al
     Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).
     J Infect Dis. 2023;228:1263-1273.
     PubMed     Abstract available
     
     
     
286. WONG JY, Cheung JK, Lin Y, Bond HS, et al
     Intrinsic and Effective Severity of Coronavirus Disease 2019 Cases Infected With the Ancestral Strain and Omicron BA.2 Variant in Hong Kong.
     J Infect Dis. 2023;228:1231-1239.
     PubMed     Abstract available
     
     
     
287. EVANS MV, Ramiadantsoa T, Kauffman K, Moody J, et al
     Sociodemographic Variables Can Guide Prioritized Testing Strategies for Epidemic Control in Resource-Limited Contexts.
     J Infect Dis. 2023;228:1189-1197.
     PubMed     Abstract available
     
     
     October 2023
288. RUDOLPH AE, Khan FL, Shah A, Singh TG, et al
     Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against symptomatic COVID-19 among immunocompetent individuals testing at a large US retail pharmacy.
     J Infect Dis. 2023 Oct 31:jiad474. doi: 10.1093.
     PubMed     Abstract available
     
     
     
289. ASAMOAH-BOAHENG M, Grunau B, Karim ME, Kirkham TL, et al
     The association of post-COVID-related symptoms and preceding SARS-CoV-2 infection among fully vaccinated paramedics in Canada.
     J Infect Dis. 2023 Oct 31:jiad475. doi: 10.1093.
     PubMed     Abstract available
     
     
     
290. TURCINOVIC J, Kuhfeldt K, Sullivan M, Landaverde L, et al
     Transmission Dynamics and Rare Clustered Transmission Within an Urban University Population Before Widespread Vaccination.
     J Infect Dis. 2023 Oct 19:jiad397. doi: 10.1093.
     PubMed     Abstract available
     
     
     
291. ANDINO R, Kirkegaard K, Macadam A, Racaniello VR, et al
     The Picornaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
292. MORABITO KM, Cassetti MC, DeRocco AJ, Deschamps AM, et al
     Viral Prototypes for Pandemic Preparedness: The Road Ahead.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
293. DALMAT RR, Hao L, Prabhu R, Rechkina E, et al
     Rapid Antigen and Antibody Microfluidic Immunofluorescence Assays Compared to Culture, PCR, and Laboratory Reference Tests: Performance in a Longitudinal Cohort.
     J Infect Dis. 2023;228:1066-1070.
     PubMed     Abstract available
     
     
     
294. TUFFY KM, Ahani B, Aksyuk AA, Avila M, et al
     Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
     J Infect Dis. 2023;228:1055-1059.
     PubMed     Abstract available
     
     
     
295. BUTT AA, Yan P, Shaikh OS, Omer SB, et al
     Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19.
     J Infect Dis. 2023;228:1033-1041.
     PubMed     Abstract available
     
     
     
296. ADHIKARI EH, Lu P, Kang YJ, McDonald AR, et al
     Diverging maternal and cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy.
     J Infect Dis. 2023 Oct 10:jiad421. doi: 10.1093.
     PubMed     Abstract available
     
     
     
297. LEDDEROSE C, Valsami EA, Elevado M, Junger WG, et al
     ATP release from influenza-infected lungs enhances neutrophil activation and promotes disease progression.
     J Infect Dis. 2023 Oct 6:jiad442. doi: 10.1093.
     PubMed     Abstract available
     
     
     
298. HSU FC, Pan LC, Huang YF, Yang CH, et al
     A Dynamic Model for Estimating the Retention Duration of Neutralizing Antibody Titers after Vaccination in a COVID-19 Convalescent Population.
     J Infect Dis. 2023 Oct 5:jiad431. doi: 10.1093.
     PubMed     Abstract available
     
     
     
299. GREWAL R, Buchan SA, Nguyen L, Nasreen S, et al
     Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged >/=50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) Study.
     J Infect Dis. 2023 Oct 5:jiad419. doi: 10.1093.
     PubMed     Abstract available
     
     
     
300. CHU WT, Reza SMS, Anibal JT, Landa A, et al
     Artificial Intelligence and Infectious Disease Imaging.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
301. HAMMOUD DA, Clifford Lane H, Jain SK
     Molecular Imaging of Infections: Advancing the Search for the Hidden Enemy.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
302. LEE E, Bates B, Kuhrt N, Andersen KM, et al
     National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative.
     J Infect Dis. 2023;228:895-906.
     PubMed     Abstract available
     
     
     
303. YUNOKI M, Kubota-Koketsu R, Imada T, Furuyama K, et al
     Changes in Anti-SARS-CoV-2 Antibody Titers of Pooled Plasma Derived From Donors in Japan: A Potential Tool for Mass-Immunity Evaluation.
     J Infect Dis. 2023;228:889-894.
     PubMed     Abstract available
     
     
     
304. SKARBINSKI J, Nugent JR, Wood MS, Liu L, et al
     Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Genomic Variation Associated With Breakthrough Infection in Northern California: A Retrospective Cohort Study.
     J Infect Dis. 2023;228:878-888.
     PubMed     Abstract available
     
     
     
305. MUNOZ-QUILES C, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A, et al
     Bronchiolitis, Regardless of Its Etiology and Severity, Is Associated With Increased Risk of Asthma: A Population-Based Study.
     J Infect Dis. 2023;228:840-850.
     PubMed     Abstract available
     
     
     September 2023
306. MADSEN AMR, Schaltz-Buchholzer F, Nielsen S, Benfield T, et al
     Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: a randomized controlled trial.
     J Infect Dis. 2023 Sep 29:jiad422. doi: 10.1093.
     PubMed     Abstract available
     
     
     
307. ANDREEV K, Jones JC, Seiler P, Kandeil A, et al
     Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023.
     J Infect Dis. 2023 Sep 28:jiad418. doi: 10.1093.
     PubMed     Abstract available
     
     
     
308. HOWA AC, Zhu Y, Wyatt D, Markus T, et al
     Estimating the Burden of Influenza Hospitalizations Across Multiple Seasons Using Capture-Recapture.
     J Infect Dis. 2023 Sep 28:jiad417. doi: 10.1093.
     PubMed     Abstract available
     
     
     
309. HAYDEN FG, Lenk RP, Epstein C, Kang LL, et al
     Oral Favipiravir Exposure and Pharmacodynamic Effects in Outpatient Adults with Acute Influenza.
     J Infect Dis. 2023 Sep 22:jiad409. doi: 10.1093.
     PubMed     Abstract available
     
     
     
310. BASU THAKUR P, Mrotz VJ, Maines TR, Belser JA, et al
     Ferrets as a mammalian model to study influenza virus-bacteria interactions.
     J Infect Dis. 2023 Sep 22:jiad408. doi: 10.1093.
     PubMed     Abstract available
     
     
     
311. CHEEMARLA NR, Watkins TA, Mihaylova VT, Foxman EF, et al
     Viral interference during influenza A-SARS-CoV-2 coinfection of the human airway epithelium and reversal by oseltamivir.
     J Infect Dis. 2023 Sep 18:jiad402. doi: 10.1093.
     PubMed     Abstract available
     
     
     
312. REBELO M, Tang C, Coelho AR, Labao-Almeida C, et al
     De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
     J Infect Dis. 2023;228:723-733.
     PubMed     Abstract available
     
     
     
313. BUTT AA, Yan P, Shaikh OS, Talisa VB, et al
     Nirmatrelvir/ritonavir Use and Hospitalizations or Death in Previously Uninfected Non-hospitalized High-risk Population with COVID-19: A matched cohort study.
     J Infect Dis. 2023 Sep 15:jiad393. doi: 10.1093.
     PubMed     Abstract available
     
     
     
314. LEROUX-ROELS I, Van Ranst M, Vandermeulen C, Abeele CV, et al
     Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
     J Infect Dis. 2023 Sep 12:jiad321. doi: 10.1093.
     PubMed     Abstract available
     
     
     
315. FROBERG J, Koomen VJCH, van der Gaast-de Jongh CE, Philipsen R, et al
     Primary exposure to SARS-CoV-2 via infection or vaccination determines mucosal antibody-dependent ACE2 binding inhibition.
     J Infect Dis. 2023 Sep 7:jiad385. doi: 10.1093.
     PubMed     Abstract available
     
     
     
316. MARTIN JM, Moehling Geffel K, Ortiz MA, Rajasundaram D, et al
     Differential Induction of Interferon Stimulated Genes by Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children During the 2018-19 Season.
     J Infect Dis. 2023 Sep 4:jiad380. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2023
317. CHEW KW, Moser C, Yeh E, Wohl DA, et al
     Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
318. EVERING TH, Moser CB, Jilg N, Yeh E, et al
     Long COVID After Bamlanivimab Treatment.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
319. MOSER CB, Chew KW, Giganti MJ, Li JZ, et al
     Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
320. MOSER CB, Chew KW, Ritz J, Newell M, et al
     Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
321. RIBEIRO RM, Choudhary MC, Deo R, Giganti MJ, et al
     Variant-Specific Viral Kinetics in Acute COVID-19.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
322. LI Y, Moser C, Aga E, Currier JS, et al
     Immune Status and SARS-CoV-2 Viral Dynamics.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
323. CURRIER JS, Moser C, Eron JJ, Chew KW, et al
     ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
324. GIGANTI MJ, Chew KW, Eron JJ, Li JZ, et al
     Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
325. WAYHAM NP, Niedecken AR, Simons JF, Chiang YY, et al
     A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
     J Infect Dis. 2023;228:555-563.
     PubMed     Abstract available
     
     
     
326. SUNG MH, Billings W, Carlock MA, Hanley HB, et al
     Assessment of humoral immune responses to repeated influenza vaccination in a multiyear cohort: a five-year follow-up.
     J Infect Dis. 2023 Aug 25:jiad319. doi: 10.1093.
     PubMed     Abstract available
     
     
     
327. SARIOL A, Vickers MA, Christensen SM, Weiskopf D, et al
     Monovalent SARS-CoV-2 mRNA vaccine does not boost Omicron-specific immune response in diabetic and control pediatric patients.
     J Infect Dis. 2023 Aug 25:jiad366. doi: 10.1093.
     PubMed     Abstract available
     
     
     
328. SUN X, Belser JA, Pulit-Penaloza JA, Brock N, et al
     Pathogenesis and transmission assessment of three swine-origin influenza A(H3N2) viruses with zoonotic risk to humans isolated in the U.S from 2017-2020.
     J Infect Dis. 2023 Aug 21:jiad359. doi: 10.1093.
     PubMed     Abstract available
     
     
     
329. MERENSTEIN C, Fitzgerald AS, Khatib LA, Graham-Wooten J, et al
     Effects of Mask Reuse on the Oropharyngeal, Skin, and Mask Microbiome.
     J Infect Dis. 2023;228:479-486.
     PubMed     Abstract available
     
     
     
330. YOUNG BR, Yang B, Wu P, Adam DC, et al
     Residential Clustering of Coronavirus Disease 2019 Cases and Efficiency of Building-Wide Compulsory Testing Notices as a Transmission Control Measure in Hong Kong.
     J Infect Dis. 2023;228:426-430.
     PubMed     Abstract available
     
     
     
331. FAUCI AS, Folkers GK
     Pandemic Preparedness and Response: Lessons From COVID-19.
     J Infect Dis. 2023;228:422-425.
     PubMed     Abstract available
     
     
     
332. ROWLEY AH, Arrollo D, Shulman ST, Torres A, et al
     Analysis of Plasmablasts From Children With Kawasaki Disease Reveals Evidence of a Convergent Antibody Response to a Specific Protein Epitope.
     J Infect Dis. 2023;228:412-421.
     PubMed     Abstract available
     
     
     
333. DUARTE LF, Vazquez Y, Diethelm-Varela B, Pavez V, et al
     Differential Sars-Cov-2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough Subjects.
     J Infect Dis. 2023 Aug 12:jiad320. doi: 10.1093.
     PubMed     Abstract available
     
     
     
334. ZAVALIS EA, Contopoulos-Ioannidis DG, Ioannidis JPA
     Transparency in Infectious Disease Research: Meta-research Survey of Specialty Journals.
     J Infect Dis. 2023;228:227-234.
     PubMed     Abstract available
     
     
     
335. ANDEREGG N, Schwab T, Borcard L, Mugglin C, et al
     Population-Based Severe Acute Respiratory Syndrome Coronavirus 2 Whole-Genome Sequencing and Contact Tracing During the Coronavirus Disease 2019 Pandemic in Switzerland.
     J Infect Dis. 2023;228:251-260.
     PubMed     Abstract available
     
     
     
336. DIMCHEFF DE, Blair CN, Zhu Y, Chappell JD, et al
     Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants.
     J Infect Dis. 2023;228:235-244.
     PubMed     Abstract available
     
     
     
337. PARASKEVIS D, Gkova M, Mellou K, Gerolymatos G, et al
     Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients.
     J Infect Dis. 2023 Aug 11:jiad324. doi: 10.1093.
     PubMed     Abstract available
     
     
     
338. WANG FZ, Zhang CH, Tang L, Rodewald LE, et al
     An observational prospective cohort study of vaccine effectiveness against SARS-CoV-2 infection of an aerosolized, inhaled adenovirus-type-5-vectored COVID-19 vaccine given as a second booster dose in Guangzhou city, China.
     J Infect Dis. 2023 Aug 11:jiad338. doi: 10.1093.
     PubMed     Abstract available
     
     
     
339. NOBLE CC, Messina NL, Pittet LF, Curtis N, et al
     Interpreting the results of trials of BCG vaccination for protection against COVID-19.
     J Infect Dis. 2023 Aug 10:jiad316. doi: 10.1093.
     PubMed     Abstract available
     
     
     
340. YOON JG, Kim YE, Choi MJ, Choi WS, et al
     Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database.
     J Infect Dis. 2023 Aug 7:jiad297. doi: 10.1093.
     PubMed     Abstract available
     
     
     
341. HALL VG, Teh BW
     COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
342. ANTINORI A, Bausch-Jurken M
     The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
343. BONANNI P, Ceddia F, Dawson R
     A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
344. SUBRAMANIAN V
     Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
345. ROUPHAEL N, Bausch-Jurken M
     COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
346. WILLICOMBE M
     Foreword: Preventing COVID-19 Among the Immunocompromised Population.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
347. PARIS R
     SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
348. FINCKH A, Ciurea A, Raptis CE, Rubbert-Roth A, et al
     Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
     J Infect Dis. 2023;228.
     PubMed     Abstract available
     
     
     
349. LIU J, Cao F, Luo C, Guo Y, et al
     Stroke Following COVID-19 Vaccination: Evidence Based on Different Designs of Real-World Studies.
     J Infect Dis. 2023 Aug 3:jiad306. doi: 10.1093.
     PubMed     Abstract available
     
     
     
350. BRAUNSTEIN SL, Wahnich A, Lazar R
     COVID-19 outcomes among people with HIV and COVID-19 in New York City.
     J Infect Dis. 2023 Aug 3:jiad311. doi: 10.1093.
     PubMed     Abstract available
     
     
     
351. COHEN LE, Hansen CL, Andrew MK, McNeil SA, et al
     Predictors of severity of influenza-related hospitalizations: Results from the Global Influenza Hospital Surveillance Network (GIHSN).
     J Infect Dis. 2023 Aug 1:jiad303. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2023
352. KARRON RA, Luongo C, Woods S, Oliva J, et al
     Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/DeltaNS2/1030s in RSV-seronegative young children.
     J Infect Dis. 2023 Jul 26:jiad281. doi: 10.1093.
     PubMed     Abstract available
     
     
     
353. SAEZ-LLORENS X, Norero X, Mussi-Pinhata MM, Luciani K, et al
     Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6-7 months of age: a phase 1/2 randomized trial.
     J Infect Dis. 2023 Jul 21:jiad271. doi: 10.1093.
     PubMed     Abstract available
     
     
     
354. EL SAHLY HM, Yildirim I, Frey SE, Winokur P, et al
     Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial.
     J Infect Dis. 2023 Jul 19:jiad276. doi: 10.1093.
     PubMed     Abstract available
     
     
     
355. JAGER M, Diem G, Sahanic S, Fux V, et al
     Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
     J Infect Dis. 2023;228:160-168.
     PubMed     Abstract available
     
     
     
356. TAIWO BO, Chew KW, Moser C, Wohl DA, et al
     Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
     J Infect Dis. 2023;228:133-142.
     PubMed     Abstract available
     
     
     
357. ONWUCHEKWA C, Moreo LM, Menon S, Machado B, et al
     Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.
     J Infect Dis. 2023;228:173-184.
     PubMed     Abstract available
     
     
     
358. ROA CC, de Los Reyes MRA, Plennevaux E, Smolenov I, et al
     Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults.
     J Infect Dis. 2023 Jul 13:jiad262. doi: 10.1093.
     PubMed     Abstract available
     
     
     
359. COMEAUX CA, Bart S, Bastian AR, Klyashtornyy V, et al
     Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
     J Infect Dis. 2023 Jul 11:jiad220. doi: 10.1093.
     PubMed     Abstract available
     
     
     
360. FERNANDEZ-GONZALEZ M, Agullo V, Garcia JA, Padilla S, et al
     T-cell immunity against SARS-CoV-2 measured by an interferon-gamma release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or Omicron variants.
     J Infect Dis. 2023 Jul 7:jiad260. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2023
361. SRINIVASA VR, Griffith MP, Waggle KD, Johnson M, et al
     Genomic Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Among University Students in Western Pennsylvania.
     J Infect Dis. 2023;228:37-45.
     PubMed     Abstract available
     
     
     
362. NAYAK N, Pati A, Pavani Y, Sahu S, et al
     CCL19 (rs3136658) and CCL21 (rs2812377) Variants Are Associated With Susceptibility and Related Mortality of SARS-CoV-2 Infection.
     J Infect Dis. 2023;228:101-102.
     PubMed    
     
     
     
363. RAMILO O, Rodriguez-Fernandez R, Mejias A
     Respiratory Syncytial Virus Infection: Old Challenges and New Approaches.
     J Infect Dis. 2023;228:4-7.
     PubMed    
     
     
     
364. FUJITA S, Uriu K, Pan L, Nao N, et al
     Impact of imprinted immunity induced by mRNA vaccination in an experimental animal model.
     J Infect Dis. 2023 Jun 27:jiad230. doi: 10.1093.
     PubMed     Abstract available
     
     
     
365. ARTENIE A, Stone J, Facente SN, Fraser H, et al
     Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
     J Infect Dis. 2023 Jun 24:jiad169. doi: 10.1093.
     PubMed     Abstract available
     
     
     
366. RODRIGUES TS, Caetano CCS, de Sa KSG, Almeida L, et al
     CASP4/11 Contributes to NLRP3 Activation and COVID-19 Exacerbation.
     J Infect Dis. 2023;227:1364-1375.
     PubMed     Abstract available
     
     
     
367. DEYOE JE, Kelly JD, Grijalva CG, Bonenfant G, et al
     Association of Culturable-Virus Detection and Household Transmission of SARS-CoV-2, California and Tennessee, 2020-2022.
     J Infect Dis. 2023;227:1343-1347.
     PubMed     Abstract available
     
     
     
368. SCHIFFER JT
     The Continuing Puzzle of Defining Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity.
     J Infect Dis. 2023;227:1339-1342.
     PubMed    
     
     
     
369. LEE KH, Won D, Kim J, Lee JA, et al
     Clinical Accuracy and Utility of Plasma Microbial Cell-Free DNA Whole-Genome Sequencing for the Diagnosis of Invasive Aspergillosis in Patients with Hematologic Malignancies or Coronavirus Disease 2019.
     J Infect Dis. 2023 Jun 15:jiad213. doi: 10.1093.
     PubMed     Abstract available
     
     
     
370. ZHOU S, Long N, Moeser M, Hill CS, et al
     Use of Next Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-CoV-2 Pandemic on HIV-1 Diagnosis and Transmission.
     J Infect Dis. 2023 Jun 7:jiad211. doi: 10.1093.
     PubMed     Abstract available
     
     
     
371. WANG W, Goguet E, Paz Padilla S, Vassell R, et al
     Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens.
     J Infect Dis. 2023 Jun 6:jiad111. doi: 10.1093.
     PubMed     Abstract available
     
     
     
372. BROWN JA, Hauser A, Abela IA, Pasin C, et al
     Seroprofiling of antibodies against endemic human coronaviruses and SARS-CoV-2 in an HIV cohort in Lesotho: correlates of antibody response and seropositivity.
     J Infect Dis. 2023 Jun 1:jiad197. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2023
373. KEELEY AJ, Groves D, Armitage EP, Senghore E, et al
     Streptococcus pyogenes colonization in children aged 24-59 months in The Gambia: Impact of Live Attenuated Influenza Vaccine and associated serological responses.
     J Infect Dis. 2023 May 29:jiad153. doi: 10.1093.
     PubMed     Abstract available
     
     
     
374. SCHIFANELLA L, Anderson J, Wieking G, Southern PJ, et al
     The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis.
     J Infect Dis. 2023;227:1245-1254.
     PubMed     Abstract available
     
     
     
375. BAKSH SN, Heath SL, Fukuta Y, Shade D, et al
     Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial.
     J Infect Dis. 2023;227:1266-1273.
     PubMed     Abstract available
     
     
     
376. FRIES L, Formica N, Mallory RM, Zhou H, et al
     Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination.
     J Infect Dis. 2023 May 21:jiad163. doi: 10.1093.
     PubMed     Abstract available
     
     
     
377. XIA X, Tan ZM, Wan P, Zheng H, et al
     Environmental impact assessment for the use of an orally aerosolised adenovirus type-5 vector-based COVID-19 vaccine in randomised clinical trials.
     J Infect Dis. 2023 May 18:jiad134. doi: 10.1093.
     PubMed     Abstract available
     
     
     
378. FORTE-SOTO P, Albayaty M, Brooks D, Arends RH, et al
     Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
     J Infect Dis. 2023;227:1153-1163.
     PubMed     Abstract available
     
     
     
379. LAWLESS D, McKennan CG, Das SR, Junier T, et al
     Viral Genetic Determinants of Prolonged Respiratory Syncytial Virus Infection Among Infants in a Healthy Term Birth Cohort.
     J Infect Dis. 2023;227:1194-1202.
     PubMed     Abstract available
     
     
     
380. SU W, Choy KT, Gu H, Sia SF, et al
     Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters.
     J Infect Dis. 2023;227:1143-1152.
     PubMed     Abstract available
     
     
     
381. DURSTENFELD MS, Peluso MJ, Kaveti P, Hill C, et al
     Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID.
     J Infect Dis. 2023 May 11:jiad131. doi: 10.1093.
     PubMed     Abstract available
     
     
     
382. ASSANTACHAI P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, et al
     Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults.
     J Infect Dis. 2023 May 4:jiad133. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2023
383. TAMAI M, Taba S, Mise T, Yamashita M, et al
     Ethanol vapor inhalation treatment inhibits lethal respiratory viral infection with Influenza A.
     J Infect Dis. 2023 Apr 27:jiad089. doi: 10.1093.
     PubMed     Abstract available
     
     
     
384. SINGH G, Abbad A, Tcheou J, Mendu DR, et al
     Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections.
     J Infect Dis. 2023 Apr 27:jiad116. doi: 10.1093.
     PubMed     Abstract available
     
     
     
385. IONESCU IG, Skowronski DM, Sauvageau C, Chuang E, et al
     BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration.
     J Infect Dis. 2023;227:1073-10783.
     PubMed     Abstract available
     
     
     
386. VAN DER MAADEN T, Mutubuki EN, de Bruijn S, Leung KY, et al
     Prevalence and Severity of Symptoms 3 Months After Infection With SARS-CoV-2 Compared to Test-Negative and Population Controls in the Netherlands.
     J Infect Dis. 2023;227:1059-1067.
     PubMed     Abstract available
     
     
     
387. KOBAYASHI H, Mori Y, Ahmed S, Hirao Y, et al
     Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
     J Infect Dis. 2023;227:1068-1072.
     PubMed     Abstract available
     
     
     
388. ALVAREZ-HEREDIA P, Reina-Alfonso I, Dominguez-Del Castillo JJ, Gutierrez-Gonzalez C, et al
     Accelerated T cell immunosenescence in CMV-seropositive individuals after SARS-CoV-2 infection.
     J Infect Dis. 2023 Apr 26:jiad119. doi: 10.1093.
     PubMed     Abstract available
     
     
     
389. HOEVE CE, de Gier B, Huiberts AJ, de Melker HE, et al
     Vaccine effectiveness against SARS-CoV-2 Delta and Omicron infection and infectiousness within households in the Netherlands between July 2021 and August 2022.
     J Infect Dis. 2023 Apr 24:jiad110. doi: 10.1093.
     PubMed     Abstract available
     
     
     
390. JORDAN E, Kabir G, Schultz S, Silbernagl G, et al
     Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: a Human Challenge Trial of MVA-BN-RSV Vaccine.
     J Infect Dis. 2023 Apr 20:jiad108. doi: 10.1093.
     PubMed     Abstract available
     
     
     
391. RAN S, Yao J, Liu B
     Association Between Coronavirus Disease 2019 and Lung Function: A Mendelian Randomization Analysis.
     J Infect Dis. 2023;227:1019-1020.
     PubMed    
     
     
     
392. HWANG HS, Lo CM, Murphy M, Grudda T, et al
     Characterizing SARS-CoV-2 Transcription of Subgenomic and Genomic RNAs During Early Human Infection Using Multiplexed Droplet Digital Polymerase Chain Reaction.
     J Infect Dis. 2023;227:981-992.
     PubMed     Abstract available
     
     
     
393. PRASAD N, Rhodes J, Deng L, McCarthy NL, et al
     Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014-2020.
     J Infect Dis. 2023;227:907-916.
     PubMed     Abstract available
     
     
     
394. TENFORDE MW, Devine OJ, Reese HE, Silk BJ, et al
     Point Prevalence Estimates of Activity-Limiting Long-term Symptoms Among United States Adults >/=1 Month After Reported Severe Acute Respiratory Syndrome Coronavirus 2 Infection, 1 November 2021.
     J Infect Dis. 2023;227:855-863.
     PubMed     Abstract available
     
     
     
395. TIMI P, Kellerhals SE, Joseph NT, Dude CM, et al
     Placental Injury and Antibody Transfer after Coronavirus Disease 2019 in Pregnancy.
     J Infect Dis. 2023;227:850-854.
     PubMed     Abstract available
     
     
     
396. BLANKSON JN
     Bivalent COVID Vaccines; Can the Original Antigenic Sin be Forgiven?
     J Infect Dis. 2023 Apr 5:jiad073. doi: 10.1093.
     PubMed    
     
     
     
397. TANG L, Wang FZ, Rodewald LE, Wang XY, et al
     Real-world effectiveness of primary series and booster doses of inactivated COVID-19 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study.
     J Infect Dis. 2023 Apr 3:jiad090. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2023
398. WINCHESTER NE, Shrestha NK, Kim P, Tereshchenko LG, et al
     Protection Conferred by Delta and BA.1/BA.2 Infection Against BA.4/BA.5 Infection and Hospitalization: A Retrospective Cohort Study.
     J Infect Dis. 2023;227:800-805.
     PubMed     Abstract available
     
     
     
399. CHU Y, Milner J, Lamb M, Maryamchik E, et al
     Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes.
     J Infect Dis. 2023;227:788-799.
     PubMed     Abstract available
     
     
     
400. THOUVENIN G, Prevost B, Corvol H
     Omicron Wave Modification of the Coronavirus Disease 2019 Paradigm in Children With Cystic Fibrosis.
     J Infect Dis. 2023;227:831-832.
     PubMed    
     
     
     
401. NURMI V, Knight C, Estcourt L, Hepojoki J, et al
     The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors.
     J Infect Dis. 2023 Mar 27:jiad070. doi: 10.1093.
     PubMed     Abstract available
     
     
     
402. SMITH CL, Bednarchik B, Aung H, Wilk DJ, et al
     Humoral and Cellular Immunity Induced by Adjuvanted and Standard Trivalent Influenza Vaccine in Older Nursing Home Residents.
     J Infect Dis. 2023 Mar 23:jiad071. doi: 10.1093.
     PubMed     Abstract available
     
     
     
403. FEDSON DS
     In-Hospital Statin Treatment of COVID-19.
     J Infect Dis. 2023;227:731-732.
     PubMed    
     
     
     
404. SUN P, Balinsky CA, Jiang L, Jani V, et al
     Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty U.S. Navy Sailors and Marines.
     J Infect Dis. 2023 Mar 1:jiad054. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2023
405. CORTESE MM, Taylor AW, Akinbami LJ, Thames-Allen A, et al
     Surveillance for multisystem inflammatory syndrome in U.S. children aged 5-11 years who received Pfizer-BioNTech COVID-19 vaccine, November 2021-March 2022.
     J Infect Dis. 2023 Feb 23:jiad051. doi: 10.1093.
     PubMed     Abstract available
     
     
     
406. BOZIO CH, Butterfield KA, Briggs Hagen M, Grannis S, et al
     Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance.
     J Infect Dis. 2023 Feb 18:jiad040. doi: 10.1093.
     PubMed     Abstract available
     
     
     
407. HUAPAYA JA, Higgins J, Kanth S, Demirkale C, et al
     Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections.
     J Infect Dis. 2023 Feb 18:jiad045. doi: 10.1093.
     PubMed     Abstract available
     
     
     
408. ALTHAUS T, Landier J, Zhu F, Raps H, et al
     The impact of SARS-CoV-2 vaccination and infection on neutralising antibodies: a nation-wide cross-sectional analysis.
     J Infect Dis. 2023 Feb 14:jiad030. doi: 10.1093.
     PubMed     Abstract available
     
     
     
409. DESANTIS SM, Yaseen A, Hao T, Leon-Novelo L, et al
     Incidence and predictors of breakthrough and severe breakthrough infections of SARS-CoV-2 after primary series vaccination in adults: A population-based survey of 22,575 participants.
     J Infect Dis. 2023 Feb 2:jiad020. doi: 10.1093.
     PubMed     Abstract available
     
     
     
410. BEBIA Z, Reyes O, Jeanfreau R, Kantele A, et al
     Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial.
     J Infect Dis. 2023 Feb 1:jiad024. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2022
411. NAKAGAMA Y, Candray K, Kaku N, Komase Y, et al
     Antibody avidity maturation, following recovery from infection or the booster vaccination, grants breadth in SARS-CoV-2 neutralizing capacity.
     J Infect Dis. 2022 Dec 22:jiac492. doi: 10.1093.
     PubMed     Abstract available
     
     
     
412. DIEZ-DOMINGO J, Saez-Llorens X, Rodriguez-Weber MA, Epalza C, et al
     Safety and immunogenicity of a ChAd155-vectored RSV vaccine (ChAd155-RSV) in healthy RSV-seropositive children 12-23 months of age.
     J Infect Dis. 2022 Dec 9:jiac481. doi: 10.1093.
     PubMed     Abstract available
     
     
     
413. SHIODA K, Chen Y, Collins MH, Lopman BA, et al
     Population-Level Relative Effectiveness of the COVID-19 Vaccines and the Contribution of Naturally Acquired Immunity.
     J Infect Dis. 2022 Dec 7:jiac483. doi: 10.1093.
     PubMed     Abstract available
     
     
     
414. GREWAL R, Nguyen L, Buchan SA, Wilson SE, et al
     Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada.
     J Infect Dis. 2022 Dec 3:jiac468. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2022
415. WANG X, Zein J, Ji X, Lin DY, et al
     Impact of Vaccination, Prior Infection and Therapy on Omicron Infection and Mortality.
     J Infect Dis. 2022 Nov 23:jiac460. doi: 10.1093.
     PubMed     Abstract available
     
     
     
416. DESILVA MB, Mitchell PK, Klein NP, Dixon BE, et al
     Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.
     J Infect Dis. 2022 Nov 23:jiac458. doi: 10.1093.
     PubMed     Abstract available
     
     
     
417. TOMETTEN I, Landmann S, Kantauskaite M, Lamberti J, et al
     Factors associated with vaccine-induced T cell immune responses against SARS-CoV-2 in kidney transplant recipients.
     J Infect Dis. 2022 Nov 21:jiac449. doi: 10.1093.
     PubMed     Abstract available
     
     
     
418. LIND ML, Copin R, McCarthy S, Coppi A, et al
     Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
     J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
     PubMed     Abstract available
     
     
     
419. JONGKEES MJ, Geers D, Hensley KS, Huisman W, et al
     Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination.
     J Infect Dis. 2022 Nov 19:jiac451. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2022
420. LEROUX-ROELS I, Davis MG, Steenackers K, Essink B, et al
     Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase I/II randomized clinical trial.
     J Infect Dis. 2022 Jul 29. pii: 6651941. doi: 10.1093.
     PubMed     Abstract available
     
     
     
421. CRISTINA CASSETTI M, Pierson TC, Jean Patterson L, Bok K, et al
     Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
     J Infect Dis. 2022 Jul 25. pii: 6649664. doi: 10.1093.
     PubMed     Abstract available
     
     
     
422. COSSU MV, Mileto D, Giacomelli A, Oreni L, et al
     Does the co-morbidity burden contribute to suboptimal immunological responses to COVID-19 vaccination in people living with HIV?
     J Infect Dis. 2022 Jul 7. pii: 6633353. doi: 10.1093.
     PubMed    
     
     
     June 2022
423. JACOBSON JM
     Immune Responses to SARS-CoV-2 Vaccination in People With HIV: A Tale of Two Pandemics.
     J Infect Dis. 2022 Jun 7. pii: 6603522. doi: 10.1093.
     PubMed    
     
     
     
424. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
     People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
     J Infect Dis. 2022 Jun 7. pii: 6603521. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.